Novel Agents for the Prevention of Breast Cancer: Targeting Transcription Factors and Signal Transduction Pathways

Journal of Mammary Gland Biology and Neoplasia - Tập 8 Số 1 - Trang 45-73 - 2003
Shen, Qiang1, Brown, Powel H.1
1Department of Molecular and Cellular Biology, Baylor College of Medicine, Breast Center, Houston

Tóm tắt

Transformation of breast cells occurs through loss or mutation of tumor suppressor genes, or activation or amplification of oncogenes, leading to deregulation of signal transduction pathways, abnormal amplification of growth signals, and aberrant expression of genes that ultimately transform the cells into invasive cancer. The goal of cancer preventive therapy, or “chemoprevention,” is to eliminate premalignant cells or to block the progression of normal cells into cancer. Multiple alterations in signal pathways and transcription factors are observed in mammary gland tumorigenesis. In particular, estrogen receptor (ER) deregulation plays a critical role in breast cancer development and progress, and targeting ER with selective ER modulators (SERMs) has achieved significant reduction of breast cancer incidence in women at high risk for breast cancer. However, not all breast cancer is prevented by SERMs, because 30–40% of the tumors are ER-negative. Other receptors for retinoids, vitamin D analogs and peroxisome proliferator–activiator, along with transcription factors such as AP-1, NF-κB, and STATs (signal transducers and activators of transcription) affect breast tumorigenesis. This is also true for the signal transduction pathways, for example cyclooxygenase 2 (Cox-2), HER2/neu, mitogen-activated protein kinase (MAPK), and PI3K/Akt. Therefore, proteins in pathways that are altered during the process of mammary tumorigenesis may be promising targets of future chemopreventive drugs. Many newly-developed synthetic or natural compounds/agents are now under testing in preclinical studies and clinical trials. Receptor selective retinoids, receptor tyrosine kinase inhibitors (TKIs), SERMs, Cox-2 inhibitors, and others are some of the promising novel agents for the prevention of breast cancer. The chemopreventive activity of these agents and other novel signal transduction inhibitors are discussed in this chapter.

Từ khóa


Tài liệu tham khảo

citation_journal_title=Carcinogenesis; citation_title=Chemoprevention of cancer; citation_author=M. B. Sporn, N. Suh; citation_volume=21; citation_publication_date=2000; citation_pages=525-530; citation_id=CR1

citation_journal_title=Clin. Cancer Res.; citation_title=Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development; citation_author=J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon, A. J. Dannenberg, W. K. Hong, C. J. Fabian, C. C. Sigman, M. M. Bertagnolli, S. P. Stratton, S. Lam, W. G. Nelson, F. L. Meyskens, D. S. Alberts, M. Follen, A. K. Rustgi, V. Papadimitrakopoulou, P. T. Scardino, A. F. Gazdar, L. W. Wattenberg, M. B. Sporn, W. A. Sakr, S. M. Lippman, D. D. Von Hoff; citation_volume=8; citation_publication_date=2002; citation_pages=314-346; citation_id=CR2

(1999). Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res. 59:4743-4758.

citation_journal_title=Cancer Res.; citation_title=Cancer prevention science and practice; citation_author=S. M. Lippman, W. K. Hong; citation_volume=62; citation_publication_date=2002; citation_pages=5119-5125; citation_id=CR4

citation_journal_title=BMJ; citation_title=Cancer chemoprevention; citation_author=P. Greenwald; citation_volume=324; citation_publication_date=2002; citation_pages=714-718; citation_id=CR5

A. C. Society (2002). Estimated New Cancer Cases and Deaths by Gender, US, 2002.

citation_title=The role of estrogen in normal breast development and breast cancer; citation_inbook_title=Natural and Synthetic Estrogens: Aspects of the Cellular and Molecular Activity; citation_publication_date=2002; citation_id=CR7; citation_author=S. M. Townson; citation_author=M. Ivanova; citation_author=A. V. Lee; citation_author=S. Oesterreich; citation_publisher=Research Signpost

citation_journal_title=Physiol Rev.; citation_title=Mechanisms of estrogen action; citation_author=S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, J. A. Gustafsson; citation_volume=81; citation_publication_date=2001; citation_pages=1535-1565; citation_id=CR8

citation_journal_title=N. Engl. J. Med.; citation_title=Tamoxifen in the treatment of breast cancer; citation_author=C. K. Osborne; citation_volume=339; citation_publication_date=1998; citation_pages=1609-1618; citation_id=CR9

citation_journal_title=Proc. Natl. Acad. Sci. U. S. A.; citation_title=Molecular determinants of tissue selectivity in estrogen receptor modulators; citation_author=T. A. Grese, J. P. Sluka, H. U. Bryant, G. J. Cullinan, A. L. Glasebrook, C. D. Jones, K. Matsumoto, A. D. Palkowitz, M. Sato, J. D. Termine, M. A. Winter, N. N. Yang, J. A. Dodge; citation_volume=94; citation_publication_date=1997; citation_pages=14105-14110; citation_id=CR10

citation_journal_title=Cancer Res.; citation_title=The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor; citation_author=J. I. Schafer, H. Liu, D. A. Tonetti, V. C. Jordan; citation_volume=59; citation_publication_date=1999; citation_pages=4308-4313; citation_id=CR11

citation_journal_title=J. Natl. Cancer Inst.; citation_title=Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth; citation_author=R. M. O'Regan, A. Cisneros, G. M. England, J. I. MacGregor, H. D. Muenzner, V. J. Assikis, M. M. Bilimoria, M. Piette, Y. P. Dragan, H. C. Pitot, R. Chatterton, V. C. Jordan; citation_volume=90; citation_publication_date=1998; citation_pages=1552-1558; citation_id=CR12

citation_journal_title=J. Natl. Cancer Inst.; citation_title=Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study; citation_author=B. Fisher, J. P. Costantino, D. L. Wickerham, C. K. Redmond, M. Kavanah, W. M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, N. Wolmark; citation_volume=90; citation_publication_date=1998; citation_pages=1371-1388; citation_id=CR13

citation_journal_title=JAMA; citation_title=The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation; citation_author=S. R. Cummings, S. Eckert, K. A. Krueger, D. Grady, T. J. Powles, J. A. Cauley, L. Norton, T. Nickelsen, N. H. Bjarnason, M. Morrow, M. E. Lippman, D. Black, J. E. Glusman, A. Costa, V. C. Jordan; citation_volume=281; citation_publication_date=1999; citation_pages=2189-2197; citation_id=CR14

citation_journal_title=Ann. N. Y. Acad. Sci.; citation_title=The Royal Marsden Hospital (RMH) trial: Key points and remaining questions; citation_author=T. J. Powles; citation_volume=949; citation_publication_date=2001; citation_pages=109-112; citation_id=CR15

citation_journal_title=Lancet; citation_title=Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study; citation_author=U. Veronesi, P. Maisonneuve, A. Costa, V. Sacchini, C. Maltoni, C. Robertson, N. Rotmensz, P. Boyle; citation_volume=352; citation_publication_date=1998; citation_pages=93-97; citation_id=CR16

citation_journal_title=Lancet; citation_title=First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial; citation_author=; citation_volume=360; citation_publication_date=2002; citation_pages=817-824; citation_id=CR17

citation_journal_title=Clin. Cancer Res.; citation_title=9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice; citation_author=K. Wu, H. T. Kim, J. L. Rodriquez, D. Munoz-Medellin, S. K. Mohsin, S. G. Hilsenbeck, W. W. Lamph, M. M. Gottardis, M. A. Shirley, J. G. Kuhn, J. E. Green, P. H. Brown; citation_volume=6; citation_publication_date=2000; citation_pages=3696-3704; citation_id=CR18

citation_journal_title=Oncogene; citation_title=The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Dsssuctal epithelial cell targeting with multistage progression to carcinoma; citation_author=J. E. Green, M. A. Shibata, K. Yoshidome, M. L. Liu, C. Jorcyk, M. R. Anver, J. Wigginton, R. Wiltrout, E. Shibata, S. Kaczmarczyk, W. Wang, Z. Y. Liu, A. Calvo, C. Couldrey; citation_volume=19; citation_publication_date=2000; citation_pages=1020-1027; citation_id=CR19

citation_journal_title=J. Clin. Oncol.; citation_title=Initial clinical trial of a selective retinoid X receptor ligand, LGD1069; citation_author=V. A. Miller, F. M. Benedetti, J. R. Rigas, A. L. Verret, D. G. Pfister, D. Straus, M. G. Kris, M. Crisp, R. Heyman, G. R. Loewen, J. A. Truglia, R. P. Warrell; citation_volume=15; citation_publication_date=1997; citation_pages=790-795; citation_id=CR20

citation_journal_title=Clin. Cancer Res.; citation_title=A Phase I study of LGD1069 in adults with advanced cancer; citation_author=N. A. Rizvi, J. L. Marshall, W. Dahut, E. Ness, J. A. Truglia, G. Loewen, G. M. Gill, E. H. Ulm, R. Geiser, D. Jaunakais, M. J. Hawkins; citation_volume=5; citation_publication_date=1999; citation_pages=1658-1664; citation_id=CR21

citation_journal_title=J. Clin. Oncol.; citation_title=Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II–III trial results; citation_author=M. Duvic, K. Hymes, P. Heald, D. Breneman, A. G. Martin, P. Myskowski, C. Crowley, R. C. Yocum; citation_volume=19; citation_publication_date=2001; citation_pages=2456-2471; citation_id=CR22

citation_journal_title=Am. J. Clin. Oncol.; citation_title=Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate; citation_author=K. J. Pienta, P. S. Esper, F. Zwas, R. Krzeminski, L. E. Flaherty; citation_volume=20; citation_publication_date=1997; citation_pages=36-39; citation_id=CR23

citation_journal_title=Br. J. Cancer; citation_title=A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer; citation_author=T. Gulliford, J. English, K. W. Colston, P. Menday, S. Moller, R. C. Coombes; citation_volume=78; citation_publication_date=1998; citation_pages=6-13; citation_id=CR24

citation_journal_title=Clin. Cancer Res.; citation_title=Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer; citation_author=G. Liu, K. Oettel, G. Ripple, M. J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, R. Marnocha, R. Bruskewitz, R. Mazess, C. Bishop, A. Bhattacharya, H. Bailey, G. Wilding; citation_volume=8; citation_publication_date=2002; citation_pages=2820-2827; citation_id=CR25

citation_journal_title=Br. J. Cancer; citation_title=A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer; citation_author=T. R. Evans, K. W. Colston, F. J. Lofts, D. Cunningham, D. A. Anthoney, H. Gogas, J. S. de Bono, K. J. Hamberg, T. Skov, J. L. Mansi; citation_volume=86; citation_publication_date=2002; citation_pages=680-685; citation_id=CR26

citation_journal_title=J. Bone Miner. Res.; citation_title=Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements; citation_author=L. Verlinden, A. Verstuyf, M. Quack, M. Van Camp, E. Van Etten, P. De Clercq, M. Vandewalle, C. Carlberg, R. Bouillon; citation_volume=16; citation_publication_date=2001; citation_pages=625-638; citation_id=CR27

citation_journal_title=Braz. J. Med. Biol. Res.; citation_title=Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: A mini review; citation_author=P. Bortman, M. A. Folgueira, M. L. Katayama, I. M. Snitcovsky, M. M. Brentani; citation_volume=35; citation_publication_date=2002; citation_pages=1-9; citation_id=CR28

citation_journal_title=Blood; citation_title=Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells; citation_author=J. Hisatake, J. O'Kelly, M. R. Uskokovic, S. Tomoyasu, H. P. Koeffler; citation_volume=97; citation_publication_date=2001; citation_pages=2427-2433; citation_id=CR29

citation_journal_title=Cancer Chemother. Pharmacol.; citation_title=The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells; citation_author=M. Chaudhry, S. Sundaram, C. Gennings, H. Carter, D. A. Gewirtz; citation_volume=47; citation_publication_date=2001; citation_pages=429-436; citation_id=CR30

citation_journal_title=Steroids; citation_title=Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners; citation_author=M. Chodynski, J. Wietrzyk, E. Marcinkowska, A. Opolski, W. Szelejewski, A. Kutner; citation_volume=67; citation_publication_date=2002; citation_pages=789-798; citation_id=CR31

citation_journal_title=Med. Res. Rev.; citation_title=Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond; citation_author=A. B. Jones; citation_volume=21; citation_publication_date=2001; citation_pages=540-552; citation_id=CR32

citation_journal_title=Eur. J. Cancer Prev.; citation_title=Linkage between retinoid and fatty acid receptors: Implications for breast cancer prevention; citation_author=B. A. Stoll; citation_volume=11; citation_publication_date=2002; citation_pages=319-325; citation_id=CR33

citation_journal_title=Breast Cancer Res. Treat.; citation_title=Novel therapeutic approach: Ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells; citation_author=E. Elstner, E. A. Williamson, C. Zang, J. Fritz, D. Heber, M. Fenner, K. Possinger, H. P. Koeffler; citation_volume=74; citation_publication_date=2002; citation_pages=155-165; citation_id=CR34

citation_journal_title=Anticancer Res.; citation_title=Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands; citation_author=G. M. Pighetti, W. Novosad, C. Nicholson, D. C. Hitt, C. Hansens, A. B. Hollingsworth, M. L. Lerner, D. Brackett, S. A. Lightfoot, J. M. Gimble; citation_volume=21; citation_publication_date=2001; citation_pages=825-829; citation_id=CR35

citation_journal_title=Mol. Carcinog.; citation_title=Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun; citation_author=M. R. Young, L. Farrell, P. Lambert, P. Awasthi, N. H. Colburn; citation_volume=34; citation_publication_date=2002; citation_pages=72-77; citation_id=CR36

citation_journal_title=Cancer Res.; citation_title=A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion; citation_author=E. J. Thompson, J. MacGowan, M. R. Young, N. Colburn, G. T. Bowden; citation_volume=62; citation_publication_date=2002; citation_pages=3044-3047; citation_id=CR37

citation_journal_title=Anticancer Res.; citation_title=Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions; citation_author=A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, H. S. Yu, S. H. Jee, G. S. Chen, T. M. Chen, C. A. Chen, M. K. Lai, Y. S. Pu, M. H. Pan, Y. J. Wang, C. C. Tsai, C. Y. Hsieh; citation_volume=21; citation_publication_date=2001; citation_pages=2895-2900; citation_id=CR38

citation_journal_title=Int. J. Cancer; citation_title=Curcumin exerts multiple suppressive effects on human breast carcinoma cells; citation_author=Z. M. Shao, Z. Z. Shen, C. H. Liu, M. R. Sartippour, V. L. Go, D. Heber, M. Nguyen; citation_volume=98; citation_publication_date=2002; citation_pages=234-240; citation_id=CR39

citation_journal_title=FEBS Lett.; citation_title=Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction; citation_author=T. Choudhuri, S. Pal, M. L. Agwarwal, T. Das, G. Sa; citation_volume=512; citation_publication_date=2002; citation_pages=334-340; citation_id=CR40

citation_journal_title=Carcinogenesis; citation_title=Potent preventive action of curcumin on radiation-induced initiation of mammary tumorigenesis in rats; citation_author=H. Inano, M. Onoda, N. Inafuku, M. Kubota, Y. Kamada, T. Osawa, H. Kobayashi, K. Wakabayashi; citation_volume=21; citation_publication_date=2000; citation_pages=1835-1841; citation_id=CR41

citation_journal_title=Cancer Lett.; citation_title=Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumorigenesis in Sencar mice; citation_author=C. C. Lin, Y. P. Lu, Y. R. Lou, C. T. Ho, H. H. Newmark, C. MacDonald, K. W. Singletary, M. T. Huang; citation_volume=168; citation_publication_date=2001; citation_pages=125-132; citation_id=CR42

citation_journal_title=Br. J. Pharmacol.; citation_title=A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat; citation_author=T. J. Huang, I. M. Adcock, K. F. Chung; citation_volume=134; citation_publication_date=2001; citation_pages=1029-1036; citation_id=CR43

citation_journal_title=Cancer Detect. Prev.; citation_title=Inhibition of nuclear factor kappaB induces apoptosis following treatment with tumor necrosis factor alpha and an antioxidant in human prostate cancer cells; citation_author=K. Gunawardena, D. K. Murray, R. E. Swope, A. W. Meikle; citation_volume=26; citation_publication_date=2002; citation_pages=229-237; citation_id=CR44

citation_journal_title=Oncogene; citation_title=The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis; citation_author=Q. G. Dong, G. M. Sclabas, S. Fujioka, C. Schmidt, B. Peng, T. Wu, M. S. Tsao, D. B. Evans, J. L. Abbruzzese, T. J. McDonnell, P. J. Chiao; citation_volume=21; citation_publication_date=2002; citation_pages=6510-6519; citation_id=CR45

citation_journal_title=Semin. Oncol.; citation_title=Hematologic malignancies: New developments and future treatments; citation_author=B. D. Cheson; citation_volume=29; citation_publication_date=2002; citation_pages=33-45; citation_id=CR46

citation_journal_title=J. Clin. Oncol.; citation_title=Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers; citation_author=J. A. Bonner, K. P. Raisch, H. Q. Trummell, F. Robert, R. F. Meredith, S. A. Spencer, D. J. Buchsbaum, M. N. Saleh, M. A. Stackhouse, A. F. LoBuglio, G. E. Peters, W. R. Carroll, H. W. Waksal; citation_volume=18; citation_publication_date=2000; citation_pages=47S-53S; citation_id=CR47

citation_journal_title=Oncogene; citation_title=Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells; citation_author=W. M. Burke, X. Jin, H. J. Lin, M. Huang, R. Liu, R. K. Reynolds, J. Lin; citation_volume=20; citation_publication_date=2001; citation_pages=7925-7934; citation_id=CR48

citation_journal_title=J. Biol. Chem.; citation_title=Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines; citation_author=L. Li, P. E. Shaw; citation_volume=277; citation_publication_date=2002; citation_pages=17397-17405; citation_id=CR49

citation_journal_title=Clin. Cancer Res.; citation_title=Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis; citation_author=S. Alas, B. Bonavida; citation_volume=9; citation_publication_date=2003; citation_pages=316-326; citation_id=CR50

citation_journal_title=Mol. Cancer Ther.; citation_title=Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone; citation_author=L. Burdelya, R. Catlett-Falcone, A. Levitzki, F. Cheng, L. B. Mora, E. Sotomayor, D. Coppola, J. Sun, S. Sebti, W. S. Dalton, R. Jove, H. Yu; citation_volume=1; citation_publication_date=2002; citation_pages=893-899; citation_id=CR51

citation_journal_title=Physiol. Rev.; citation_title=Nuclear hormone receptors and gene expression; citation_author=A. Aranda, A. Pascual; citation_volume=81; citation_publication_date=2001; citation_pages=1269-1304; citation_id=CR52

citation_journal_title=Cancer Res.; citation_title=Induction of retinoid resistance in breast cancer cells by overexpression of cJun; citation_author=L. Yang, H. T. Kim, D. Munoz-Medellin, P. Reddy, P. H. Brown; citation_volume=57; citation_publication_date=1997; citation_pages=4652-4661; citation_id=CR53

citation_journal_title=Cancer Res.; citation_title=9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein; citation_author=M. Rubin, E. Fenig, A. Rosenauer, C. Menendez-Botet, C. Achkar, J. M. Bentel, J. Yahalom, J. Mendelsohn, W. H. Miller; citation_volume=54; citation_publication_date=1994; citation_pages=6549-6556; citation_id=CR54

citation_journal_title=Cancer Res.; citation_title=Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen; citation_author=M. A. Anzano, S. W. Byers, J. M. Smith, C. W. Peer, L. T. Mullen, C. C. Brown, A. B. Roberts, M. B. Sporn; citation_volume=54; citation_publication_date=1994; citation_pages=4614-4617; citation_id=CR55

citation_journal_title=Clin. Cancer Res.; citation_title=Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid; citation_author=V. A. Miller, J. R. Rigas, F. M. Benedetti, A. L. Verret, W. P. Tong, M. G. Kris, G. M. Gill, G. R. Loewen, J. A. Truglia, E. H. Ulm, R. P. Warrell; citation_volume=2; citation_publication_date=1996; citation_pages=471-475; citation_id=CR56

citation_journal_title=Exp. Cell Biol.; citation_title=Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation; citation_author=J. A. Fontana; citation_volume=55; citation_publication_date=1987; citation_pages=136-144; citation_id=CR57

citation_journal_title=Cancer Treat. Rev.; citation_title=Fenretinide and its relation to cancer; citation_author=E. Ulukaya, E. J. Wood; citation_volume=25; citation_publication_date=1999; citation_pages=229-235; citation_id=CR58

citation_journal_title=Cancer Res.; citation_title=N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat; citation_author=R. C. Moon, H. J. Thompson, P. J. Becci, C. J. Grubbs, R. J. Gander, D. L. Newton, J. M. Smith, S. L. Phillips, W. R. Henderson, L. T. Mullen, C. C. Brown, M. B. Sporn; citation_volume=39; citation_publication_date=1979; citation_pages=1339-1346; citation_id=CR59

citation_journal_title=Cancer Res.; citation_title=Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats; citation_author=T. A. Ratko, C. J. Detrisac, N. M. Dinger, C. F. Thomas, G. J. Kelloff, R. C. Moon; citation_volume=49; citation_publication_date=1989; citation_pages=4472-4476; citation_id=CR60

citation_journal_title=Anticancer Res.; citation_title=Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen; citation_author=R. C. Moon, G. J. Kelloff, C. J. Detrisac, V. E. Steele, C. F. Thomas, C. C. Sigman; citation_volume=12; citation_publication_date=1992; citation_pages=1147-1153; citation_id=CR61

citation_journal_title=J. Natl. Cancer Inst.; citation_title=Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer; citation_author=U. Veronesi, G. De Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. R. Del Turco, M. G. Di Mauro, M. G. Muraca, M. Del Vecchio, C. Pinto, G. D'Aiuto, C. Boni, T. Campa, A. Magni, R. Miceli, M. Perloff, W. F. Malone, M. B. Sporn; citation_volume=91; citation_publication_date=1999; citation_pages=1847-1856; citation_id=CR62

citation_journal_title=Kurume Med. J.; citation_title=Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer; citation_author=Y. Aoyama; citation_volume=49; citation_publication_date=2002; citation_pages=27-33; citation_id=CR63

citation_journal_title=Clin. Cancer Res.; citation_title=Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia; citation_author=S. E. Singletary, E. N. Atkinson, A. Hoque, N. Sneige, A. A. Sahin, H. A. Fritsche, R. Lotan, T. Lu, W. N. Hittelman, T. B. Bevers, C. B. Stelling, S. M. Lippman; citation_volume=8; citation_publication_date=2002; citation_pages=2835-2842; citation_id=CR64

citation_journal_title=Cancer Res.; citation_title=Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand; citation_author=M. M. Gottardis, E. D. Bischoff, M. A. Shirley, M. A. Wagoner, W. W. Lamph, R. A. Heyman; citation_volume=56; citation_publication_date=1996; citation_pages=5566-5570; citation_id=CR65

citation_journal_title=Cancer Epidemiol. Biomarkers Prev.; citation_title=Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069; citation_author=K. Wu, H. T. Kim, J. L. Rodriquez, S. G. Hilsenbeck, S. K. Mohsin, X. C. Xu, W. W. Lamph, J. G. Kuhn, J. E. Green, P. H. Brown; citation_volume=11; citation_publication_date=2002; citation_pages=467-474; citation_id=CR66

citation_journal_title=Cancer Res.; citation_title=The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice; citation_author=K. Wu, Y. Zhang, X. C. Xu, J. Hill, J. Celestino, H. T. Kim, S. K. Mohsin, S. G. Hilsenbeck, W. W. Lamph, R. Bissonette, P. H. Brown; citation_volume=62; citation_publication_date=2002; citation_pages=6376-6380; citation_id=CR67

citation_journal_title=Cancer Res.; citation_title=Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma; citation_author=E. D. Bischoff, M. M. Gottardis, T. E. Moon, R. A. Heyman, W. W. Lamph; citation_volume=58; citation_publication_date=1998; citation_pages=479-484; citation_id=CR68

citation_journal_title=Clin. Cancer Res.; citation_title=Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268; citation_author=N. Suh, W. W. Lamph, A. L. Glasebrook, T. A. Grese, A. D. Palkowitz, C. R. Williams, R. Risingsong, M. R. Farris, R. A. Heyman, M. B. Sporn; citation_volume=8; citation_publication_date=2002; citation_pages=3270-3275; citation_id=CR69

citation_journal_title=Cancer Res.; citation_title=Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture; citation_author=R. J. Frampton, L. J. Suva, J. A. Eisman, D. M. Findlay, G. E. Moore, J. M. Moseley, T. J. Martin; citation_volume=42; citation_publication_date=1982; citation_pages=1116-1119; citation_id=CR70

citation_journal_title=Cancer Res.; citation_title=Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer; citation_author=J. A. Eisman, L. J. Suva, E. Sher, P. J. Pearce, J. W. Funder, T. J. Martin; citation_volume=41; citation_publication_date=1981; citation_pages=5121-5124; citation_id=CR71

citation_journal_title=Histochem. J.; citation_title=Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer; citation_author=M. Friedrich, R. Axt-Fliedner, C. Villena-Heinsen, W. Tilgen, W. Schmidt, J. Reichrath; citation_volume=34; citation_publication_date=2002; citation_pages=35-40; citation_id=CR72

citation_journal_title=J. Steroid Biochem. Mol. Biol.; citation_title=Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells; citation_author=M. T. Escaleira, S. Sonohara, M. M. Brentani; citation_volume=45; citation_publication_date=1993; citation_pages=257-263; citation_id=CR73

citation_journal_title=J. Steroid Biochem.; citation_title=1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20); citation_author=C. Chouvet, E. Vicard, M. Devonec, S. Saez; citation_volume=24; citation_publication_date=1986; citation_pages=373-376; citation_id=CR74

citation_journal_title=Breast Cancer Res. Treat.; citation_title=Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: Regulation by growth-modulatory agents, differentiation, and Ha-ras transformation; citation_author=M. T. Escaleira, M. M. Brentani; citation_volume=54; citation_publication_date=1999; citation_pages=123-133; citation_id=CR75

citation_journal_title=Eur. J. Cancer; citation_title=Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells; citation_author=S. P. Xie, G. Pirianov, K. W. Colston; citation_volume=35; citation_publication_date=1999; citation_pages=1717-1723; citation_id=CR76

citation_journal_title=Int. J. Oncol.; citation_title=Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1Alpha-hydroxyvitamin D5; citation_author=R. R. Mehta, L. Bratescu, J. M. Graves, A. Green, R. G. Mehta; citation_volume=16; citation_publication_date=2000; citation_pages=65-73; citation_id=CR77

citation_journal_title=Cancer Res.; citation_title=Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo; citation_author=L. Verlinden, A. Verstuyf, M. Van Camp, S. Marcelis, K. Sabbe, X. Y. Zhao, P. De Clercq, M. Vandewalle, R. Bouillon; citation_volume=60; citation_publication_date=2000; citation_pages=2673-2679; citation_id=CR78

citation_journal_title=Science; citation_title=The steroid and thyroid hormone receptor superfamily; citation_author=R. M. Evans; citation_volume=240; citation_publication_date=1988; citation_pages=889-895; citation_id=CR79

citation_journal_title=Curr. Opin. Lipidol.; citation_title=Peroxisome proliferator-activated receptors, orphans with ligands and functions; citation_author=K. Schoonjans, G. Martin, B. Staels, J. Auwerx; citation_volume=8; citation_publication_date=1997; citation_pages=159-166; citation_id=CR80

citation_journal_title=Biochim. Biophys. Acta.; citation_title=The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation; citation_author=K. Schoonjans, B. Staels, J. Auwerx; citation_volume=1302; citation_publication_date=1996; citation_pages=93-109; citation_id=CR81

citation_journal_title=Annu. Rev. Med.; citation_title=The mechanisms of action of PPARs; citation_author=J. Berger, D. E. Moller; citation_volume=53; citation_publication_date=2002; citation_pages=409-435; citation_id=CR82

citation_journal_title=Diabetologia; citation_title=PPARgamma, the ultimate thrifty gene; citation_author=J. Auwerx; citation_volume=42; citation_publication_date=1999; citation_pages=1033-1049; citation_id=CR83

citation_journal_title=Lung Cancer; citation_title=Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: Correlation with histological type and grade; citation_author=S. Theocharis, H. Kanelli, E. Politi, A. Margeli, C. Karkandaris, T. Philippides, A. Koutselinis; citation_volume=36; citation_publication_date=2002; citation_pages=249-255; citation_id=CR84

citation_journal_title=Prostate; citation_title=Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer; citation_author=Y. Segawa, R. Yoshimura, T. Hase, T. Nakatani, S. Wada, Y. Kawahito, T. Kishimoto, H. Sano; citation_volume=51; citation_publication_date=2002; citation_pages=108-116; citation_id=CR85

citation_journal_title=Mol. Carcinog.; citation_title=Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231; citation_author=K. M. Suchanek, F. J. May, J. A. Robinson, W. J. Lee, N. A. Holman, G. R. Monteith, S. J. Roberts-Thomson; citation_volume=34; citation_publication_date=2002; citation_pages=165-171; citation_id=CR86

citation_journal_title=Int. J. Biochem. Cell Biol.; citation_title=Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin; citation_author=K. M. Suchanek, F. J. May, W. J. Lee, N. A. Holman, S. J. Roberts-Thomson; citation_volume=34; citation_publication_date=2002; citation_pages=1051-1058; citation_id=CR87

citation_journal_title=Int. J. Oncol.; citation_title=Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review); citation_author=A. F. Badawi, M. Z. Badr; citation_volume=20; citation_publication_date=2002; citation_pages=1109-1122; citation_id=CR88

citation_journal_title=Mol. Cell Endocrinol.; citation_title=Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells; citation_author=X. Wang, M. W. Kilgore; citation_volume=194; citation_publication_date=2002; citation_pages=123-133; citation_id=CR89

citation_journal_title=J. Cell Sci.; citation_title=The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells; citation_author=M. Pignatelli, M. Cortes-Canteli, C. Lai, A. Santos, A. Perez-Castillo; citation_volume=114; citation_publication_date=2001; citation_pages=4117-4126; citation_id=CR90

citation_journal_title=Nat. Med.; citation_title=Differentiation and reversal of malignant changes in colon cancer through PPARgamma; citation_author=P. Sarraf, E. Mueller, D. Jones, F. J. King, D. J. DeAngelo, J. B. Partridge, S. A. Holden, L. B. Chen, S. Singer, C. Fletcher, B. M. Spiegelman; citation_volume=4; citation_publication_date=1998; citation_pages=1046-1052; citation_id=CR91

citation_journal_title=Cancer Res.; citation_title=Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo; citation_author=T. Kubota, K. Koshizuka, E. A. Williamson, H. Asou, J. W. Said, S. Holden, I. Miyoshi, H. P. Koeffler; citation_volume=58; citation_publication_date=1998; citation_pages=3344-3352; citation_id=CR92

citation_journal_title=Proc. Natl. Acad. Sci. U. S. A.; citation_title=Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice; citation_author=E. Elstner, C. Muller, K. Koshizuka, E. A. Williamson, D. Park, H. Asou, P. Shintaku, J. W. Said, D. Heber, H. P. Koeffler; citation_volume=95; citation_publication_date=1998; citation_pages=8806-8811; citation_id=CR93

citation_journal_title=Cancer Res.; citation_title=Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats; citation_author=T. Tanaka, H. Kohno, S. Yoshitani, S. Takashima, A. Okumura, A. Murakami, M. Hosokawa; citation_volume=61; citation_publication_date=2001; citation_pages=2424-2428; citation_id=CR94

citation_journal_title=Nat. Med.; citation_title=Activators of the nuclear receptor PPARgamma enhance colon polyp formation; citation_author=E. Saez, P. Tontonoz, M. C. Nelson, J. G. Alvarez, U. T. Ming, S. M. Baird, V. A. Thomazy, R. M. Evans; citation_volume=4; citation_publication_date=1998; citation_pages=1058-1061; citation_id=CR95

citation_journal_title=Nat. Med.; citation_title=Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice; citation_author=A. M. Lefebvre, I. Chen, P. Desreumaux, J. Najib, J. C. Fruchart, K. Geboes, M. Briggs, R. Heyman, J. Auwerx; citation_volume=4; citation_publication_date=1998; citation_pages=1053-1057; citation_id=CR96

citation_journal_title=Trends Mol. Med.; citation_title=Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs); citation_author=M. B. Sporn, N. Suh, D. J. Mangelsdorf; citation_volume=7; citation_publication_date=2001; citation_pages=395-400; citation_id=CR97

citation_journal_title=Gastroenterology; citation_title=Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice; citation_author=E. Osawa, A. Nakajima, K. Wada, S. Ishimine, N. Fujisawa, T. Kawamori, N. Matsuhashi, T. Kadowaki, M. Ochiai, H. Sekihara, H. Nakagama; citation_volume=124; citation_publication_date=2003; citation_pages=361-367; citation_id=CR98

citation_journal_title=J. Natl. Cancer Inst.; citation_title=A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions; citation_author=R. G. Mehta, E. Williamson, M. K. Patel, H. P. Koeffler; citation_volume=92; citation_publication_date=2000; citation_pages=418-423; citation_id=CR99

citation_journal_title=Proc. Natl. Acad. Sci. U. S. A.; citation_title=Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation; citation_author=J. T. Holt, T. V. Gopal, A. D. Moulton, A. W. Nienhuis; citation_volume=83; citation_publication_date=1986; citation_pages=4794-4798; citation_id=CR100

citation_journal_title=Cell Growth Differ.; citation_title=The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation; citation_author=E. Szabo, L. H. Preis, P. H. Brown, M. J. Birrer; citation_volume=2; citation_publication_date=1991; citation_pages=475-482; citation_id=CR101

citation_journal_title=Neuron; citation_title=A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death; citation_author=J. Ham, C. Babij, J. Whitfield, C. M. Pfarr, D. Lallemand, M. Yaniv, L. L. Rubin; citation_volume=14; citation_publication_date=1995; citation_pages=927-939; citation_id=CR102

citation_journal_title=Oncogene; citation_title=Suppression of oncogene-induced transformation by a deletion mutant of c-jun; citation_author=P. H. Brown, R. Alani, L. H. Preis, E. Szabo, M. J. Birrer; citation_volume=8; citation_publication_date=1993; citation_pages=877-886; citation_id=CR103

citation_journal_title=Oncogene; citation_title=Mechanism of action of a dominant-negative mutant of c-Jun; citation_author=P. H. Brown, T. K. Chen, M. J. Birrer; citation_volume=9; citation_publication_date=1994; citation_pages=791-799; citation_id=CR104

citation_journal_title=Ann. N. Y. Acad. Sci.; citation_title=Matrix metalloproteinase gene expression; citation_author=L. M. Matrisian; citation_volume=732; citation_publication_date=1994; citation_pages=42-50; citation_id=CR105

citation_journal_title=Mol. Cell. Biol.; citation_title=12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region; citation_author=P. Angel, I. Baumann, B. Stein, H. Delius, H. J. Rahmsdorf, P. Herrlich; citation_volume=7; citation_publication_date=1987; citation_pages=2256-2266; citation_id=CR106

citation_journal_title=Mol. Cell. Biol.; citation_title=Epidermal growth factor stimulation of stromelysin mRNA in rat fibroblasts requires induction of proto-oncogenes c-fos and c-jun and activation of protein kinase C; citation_author=S. E. McDonnell, L. D. Kerr, L. M. Matrisian; citation_volume=10; citation_publication_date=1990; citation_pages=4284-4293; citation_id=CR107

citation_journal_title=Invasion Metastasis; citation_title=Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines; citation_author=A. R. Mackay, M. Ballin, M. D. Pelina, A. R. Farina, A. M. Nason, J. L. Hartzler, U. P. Thorgeirsson; citation_volume=12; citation_publication_date=1992; citation_pages=168-184; citation_id=CR108

citation_journal_title=Mol. Carcinog.; citation_title=Activation and inhibition of the AP-1 complex in human breast cancer cells; citation_author=T. K. Chen, L. M. Smith, D. K. Gebhardt, M. J. Birrer, P. H. Brown; citation_volume=15; citation_publication_date=1996; citation_pages=215-226; citation_id=CR109

citation_journal_title=Oncogene; citation_title=AP-1 blockade inhibits the growth of normal and malignant breast cells; citation_author=J. H. Ludes-Meyers, Y. Liu, D. Munoz-Medellin, S. G. Hilsenbeck, P. H. Brown; citation_volume=20; citation_publication_date=2001; citation_pages=2771-2780; citation_id=CR110

citation_journal_title=Int. J. Cancer; citation_title=Biological and clinical associations of c-jun activation in human breast cancer; citation_author=J. M. Gee, A. F. Barroso, I. O. Ellis, J. F. Robertson, R. I. Nicholson; citation_volume=89; citation_publication_date=2000; citation_pages=177-186; citation_id=CR111

citation_journal_title=Int. J. Cancer; citation_title=Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype; citation_author=A. M. Bamberger, C. Methner, B. W. Lisboa, C. Stadtler, H. M. Schulte, T. Loning, K. Milde-Langosch; citation_volume=84; citation_publication_date=1999; citation_pages=533-538; citation_id=CR112

citation_journal_title=Mol. Cell. Biol.; citation_title=A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers; citation_author=Z. Tang, I. Treilleux, M. Brown; citation_volume=17; citation_publication_date=1997; citation_pages=1274-1280; citation_id=CR113

citation_journal_title=Oncogene; citation_title=cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype; citation_author=L. M. Smith, S. C. Wise, D. T. Hendricks, A. L. Sabichi, T. Bos, P. Reddy, P. H. Brown, M. J. Birrer; citation_volume=18; citation_publication_date=1999; citation_pages=6063-6070; citation_id=CR114

citation_journal_title=J. Natl. Cancer Inst.; citation_title=Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo; citation_author=R. Schiff, P. Reddy, M. Ahotupa, E. Coronado-Heinsohn, M. Grim, S. G. Hilsenbeck, R. Lawrence, S. Deneke, R. Herrera, G. C. Chamness, S. A. Fuqua, P. H. Brown, C. K. Osborne; citation_volume=92; citation_publication_date=2000; citation_pages=1926-1934; citation_id=CR115

citation_journal_title=Clin. Cancer Res.; citation_title=Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance; citation_author=S. R. Johnston, B. Lu, G. K. Scott, P. J. Kushner, I. E. Smith, M. Dowsett, C. C. Benz; citation_volume=5; citation_publication_date=1999; citation_pages=251-256; citation_id=CR116

citation_journal_title=Breast Cancer Res. Treat.; citation_title=Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells; citation_author=P. J. Daschner, H. P. Ciolino, C. A. Plouzek, G. C. Yeh; citation_volume=53; citation_publication_date=1999; citation_pages=229-240; citation_id=CR117

citation_journal_title=Oncogene; citation_title=Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth; citation_author=Y. Liu, J. Ludes-Meyers, Y. Zhang, D. Munoz-Medellin, H. T. Kim, C. Lu, G. Ge, R. Schiff, S. G. Hilsenbeck, C. K. Osborne, P. H. Brown; citation_volume=21; citation_publication_date=2002; citation_pages=7680-7689; citation_id=CR118

citation_journal_title=Proc. Natl. Acad. Sci. U. S. A.; citation_title=Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion; citation_author=M. R. Young, J. J. Li, M. Rincon, R. A. Flavell, B. K. Sathyanarayana, R. Hunziker, N. Colburn; citation_volume=96; citation_publication_date=1999; citation_pages=9827-9832; citation_id=CR119

citation_journal_title=Transplant. Proc.; citation_title=A novel inhibitor of nuclear factor-kappa B and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo; citation_author=M. Morikawa, R. A. Shorthouse, M. J. Suto, M. E. Goldman, R. E. Morris; citation_volume=29; citation_publication_date=1997; citation_pages=1269-1270; citation_id=CR120

citation_journal_title=Bioorg Med. Chem.; citation_title=Antitumor agents. Part 214: Synthesis and evaluation of curcumin analogues as cytotoxic agents; citation_author=J. Ishida, H. Ohtsu, Y. Tachibana, Y. Nakanishi, K. F. Bastow, M. Nagai, H. K. Wang, H. Itokawa, K. H. Lee; citation_volume=10; citation_publication_date=2002; citation_pages=3481-3487; citation_id=CR121

citation_journal_title=Carcinogenesis; citation_title=Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays; citation_author=H. Inano, M. Onoda, N. Inafuku, M. Kubota, Y. Kamada, T. Osawa, H. Kobayashi, K. Wakabayashi; citation_volume=20; citation_publication_date=1999; citation_pages=1011-1018; citation_id=CR122

citation_journal_title=Cancer Lett.; citation_title=Inhibition of benzo[a]pyrene-and 1,6-dinitropyrene-DNA adduct formation in human mammary epithelial cells by dibenzoylmethane and sulforaphane; citation_author=K. Singletary, C. MacDonald; citation_volume=155; citation_publication_date=2000; citation_pages=47-54; citation_id=CR123

citation_journal_title=Am. J. Pathol.; citation_title=New insights into the role of nuclear factor-kappaB in cell growth regulation; citation_author=F. Chen, V. Castranova, X. Shi; citation_volume=159; citation_publication_date=2001; citation_pages=387-397; citation_id=CR124

citation_journal_title=Annu. Rev. Immunol.; citation_title=Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity; citation_author=M. Karin, Y. Ben-Neriah; citation_volume=18; citation_publication_date=2000; citation_pages=621-663; citation_id=CR125

citation_journal_title=Oncogene; citation_title=Activators and target genes of Rel/NF-kappaB transcription factors; citation_author=H. L. Pahl; citation_volume=18; citation_publication_date=1999; citation_pages=6853-6866; citation_id=CR126

citation_journal_title=Oncogene; citation_title=The Rel/NF-kappaB signal transduction pathway: Introduction; citation_author=T. D. Gilmore; citation_volume=18; citation_publication_date=1999; citation_pages=6842-6844; citation_id=CR127

citation_journal_title=Cancer; citation_title=Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck; citation_author=J. C. Pena, C. B. Thompson, W. Recant, E. E. Vokes, C. M. Rudin; citation_volume=85; citation_publication_date=1999; citation_pages=164-170; citation_id=CR128

citation_journal_title=Int. J. Cancer; citation_title=Over-expression of bcl-xL gene in human gastric adenomas and carcinomas; citation_author=S. Kondo, Y. Shinomura, S. Kanayama, Y. Higashimoto, J. I. Miyagawa, T. Minami, T. Kiyohara, S. Zushi, S. Kitamura, K. Isozaki, Y. Matsuzawa; citation_volume=68; citation_publication_date=1996; citation_pages=727-730; citation_id=CR129

citation_journal_title=FEBS Lett.; citation_title=Making decisions through Myc; citation_author=S. Nasi, R. Ciarapica, R. Jucker, J. Rosati, L. Soucek; citation_volume=490; citation_publication_date=2001; citation_pages=153-162; citation_id=CR130

citation_journal_title=Clin. Cancer Res.; citation_title=Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial; citation_author=I. V. Boiko, M. F. Mitchell, W. Hu, D. K. Pandey, P. Mathevet, A. Malpica, W. N. Hittelman; citation_volume=4; citation_publication_date=1998; citation_pages=1383-1391; citation_id=CR131

citation_journal_title=Proc. Natl. Acad. Sci. U. S. A.; citation_title=Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism; citation_author=J. Langenfeld, H. Kiyokawa, D. Sekula, J. Boyle, E. Dmitrovsky; citation_volume=94; citation_publication_date=1997; citation_pages=12070-12074; citation_id=CR132

citation_journal_title=J. Biol. Chem.; citation_title=Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells; citation_author=S. Philip, A. Bulbule, G. C. Kundu; citation_volume=276; citation_publication_date=2001; citation_pages=44926-44935; citation_id=CR133

citation_journal_title=J. Biol. Chem.; citation_title=Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms; citation_author=E. Heiss, C. Herhaus, K. Klimo, H. Bartsch, C. Gerhauser; citation_volume=276; citation_publication_date=2001; citation_pages=32008-32015; citation_id=CR134

citation_journal_title=Cancer Res.; citation_title=Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells; citation_author=R. Romieu-Mourez, E. Landesman-Bollag, D. C. Seldin, G. E. Sonenshein; citation_volume=62; citation_publication_date=2002; citation_pages=6770-6778; citation_id=CR135

citation_journal_title=Biochem. Pharmacol.; citation_title=Identification of cytokine-induced nuclear factor-kappaB target genes in ovarian and breast cancer cells; citation_author=V. Deregowski, S. Delhalle, V. Benoit, V. Bours, M. P. Merville; citation_volume=64; citation_publication_date=2002; citation_pages=873-881; citation_id=CR136

citation_journal_title=Biochem. Biophys. Res. Commun.; citation_title=Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells; citation_author=D. Sliva, C. Labarrere, V. Slivova, M. Sedlak, F. P. Lloyd, N. W. Ho; citation_volume=298; citation_publication_date=2002; citation_pages=603-612; citation_id=CR137

citation_journal_title=Mol. Biol. Cell.; citation_title=Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium; citation_author=D. M. Brantley, C. L. Chen, R. S. Muraoka, P. B. Bushdid, J. L. Bradberry, F. Kittrell, D. Medina, L. M. Matrisian, L. D. Kerr, F. E. Yull; citation_volume=12; citation_publication_date=2001; citation_pages=1445-1455; citation_id=CR138

citation_journal_title=J. Cell. Physiol.; citation_title=TNFalpha induces NFkappaB/p50 in association with the growth and morphogenesis of normal and transformed rat mammary epithelial cells; citation_author=L. M. Varela, N. C. Stangle-Castor, S. F. Shoemaker, W. K. Shea-Eaton, M. M. Ip; citation_volume=188; citation_publication_date=2001; citation_pages=120-131; citation_id=CR139

citation_journal_title=Biochem. Pharmacol.; citation_title=Nuclear factor-kappa B and cancer: its role in prevention and therapy; citation_author=A. C. Bharti, B. B. Aggarwal; citation_volume=64; citation_publication_date=2002; citation_pages=883-888; citation_id=CR140

citation_journal_title=J. Pharmacol. Exp. Ther.; citation_title=Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages; citation_author=J. S. Kang, Y. J. Jeon, H. M. Kim, S. H. Han, K. H. Yang; citation_volume=302; citation_publication_date=2002; citation_pages=138-144; citation_id=CR141

citation_journal_title=Cancer Res.; citation_title=Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase; citation_author=S. K. Manna, N. K. Sah, R. A. Newman, A. Cisneros, B. B. Aggarwal; citation_volume=60; citation_publication_date=2000; citation_pages=3838-3847; citation_id=CR142

citation_journal_title=J. Immunol.; citation_title=Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation; citation_author=K. Ashikawa, S. Majumdar, S. Banerjee, A. C. Bharti, S. Shishodia, B. B. Aggarwal; citation_volume=169; citation_publication_date=2002; citation_pages=6490-6497; citation_id=CR143

citation_journal_title=Oncogene; citation_title=Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells; citation_author=A. Kumar, S. Dhawan, B. B. Aggarwal; citation_volume=17; citation_publication_date=1998; citation_pages=913-918; citation_id=CR144

citation_journal_title=Cancer Res.; citation_title=Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia; citation_author=C. Tan, T. A. Waldmann; citation_volume=62; citation_publication_date=2002; citation_pages=1083-1086; citation_id=CR145

citation_journal_title=Blood; citation_title=Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications; citation_author=N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. C. Munshi, S. P. Treon, K. C. Anderson; citation_volume=99; citation_publication_date=2002; citation_pages=4525-4530; citation_id=CR146

citation_journal_title=Annu. Rev. Biochem.; citation_title=Transcriptional responses to polypeptide ligands: The JAK-STAT pathway; citation_author=C. Schindler, J. E. Darnell; citation_volume=64; citation_publication_date=1995; citation_pages=621-651; citation_id=CR147

citation_journal_title=Trends Genet.; citation_title=Jaks and Stats in signaling by the cytokine receptor superfamily; citation_author=J. N. Ihle, I. M. Kerr; citation_volume=11; citation_publication_date=1995; citation_pages=69-74; citation_id=CR148

citation_journal_title=Nat. Rev. Mol. Cell. Biol.; citation_title=Stats: Transcriptional control and biological impact; citation_author=D. E. Levy, J. E. Darnell; citation_volume=3; citation_publication_date=2002; citation_pages=651-662; citation_id=CR149

citation_journal_title=Oncogene; citation_title=Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells; citation_author=R. Garcia, T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. Muro-Cacho, C. E. Cox, R. Falcone, R. Fairclough, S. Parsons, A. Laudano, A. Gazit, A. Levitzki, A. Kraker, R. Jove; citation_volume=20; citation_publication_date=2001; citation_pages=2499-2513; citation_id=CR150

citation_journal_title=J. Mam. Gland Biol. Neoplasia; citation_title=Developing a mammary gland is a stat affair; citation_author=L. Hennighausen, G. W. Robinson, K. U. Wagner, X. Liu; citation_volume=2; citation_publication_date=1997; citation_pages=365-372; citation_id=CR151

citation_journal_title=Int. J. Oncol.; citation_title=EGFR dependent expression of STAT3 (but not STAT1) in breast cancer; citation_author=G. Berclaz, H. J. Altermatt, V. Rohrbach, A. Siragusa, E. Dreher, P. D. Smith; citation_volume=19; citation_publication_date=2001; citation_pages=1155-1160; citation_id=CR152

citation_journal_title=Mol. Cancer Res.; citation_title=Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis; citation_author=E. Iavnilovitch, B. Groner, I. Barash; citation_volume=1; citation_publication_date=2002; citation_pages=32-47; citation_id=CR153

citation_journal_title=Genes Dev.; citation_title=Stat5a is mandatory for adult mammary gland development and lactogenesis; citation_author=X. Liu, G. W. Robinson, K. U. Wagner, L. Garrett, A. Wynshaw-Boris, L. Hennighausen; citation_volume=11; citation_publication_date=1997; citation_pages=179-186; citation_id=CR154

citation_journal_title=Oncogene; citation_title=Loss of Stat5a delays mammary cancer progression in a mouse model; citation_author=S. Ren, H. R. Cai, M. Li, P. A. Furth; citation_volume=21; citation_publication_date=2002; citation_pages=4335-4339; citation_id=CR155

citation_journal_title=Science; citation_title=Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases; citation_author=G. L. Johnson, R. Lapadat; citation_volume=298; citation_publication_date=2002; citation_pages=1911-1912; citation_id=CR156

citation_journal_title=Endocr. Rev.; citation_title=Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions; citation_author=G. Pearson, F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K. Berman, M. H. Cobb; citation_volume=22; citation_publication_date=2001; citation_pages=153-183; citation_id=CR157

citation_journal_title=J. Biol. Chem.; citation_title=Components of a new human protein kinase signal transduction pathway; citation_author=G. Zhou, Z. Q. Bao, J. E. Dixon; citation_volume=270; citation_publication_date=1995; citation_pages=12665-12669; citation_id=CR158

citation_journal_title=J. Biol. Chem.; citation_title=ERK8, a new member of the mitogen-activated protein kinase family; citation_author=M. K. Abe, M. P. Saelzler, R. Espinosa, K. T. Kahle, M. B. Hershenson, M. M. Le Beau, M. R. Rosner; citation_volume=277; citation_publication_date=2002; citation_pages=16733-16743; citation_id=CR159

citation_journal_title=J. Biol. Chem.; citation_title=ERK7 is an autoactivated member of the MAPK family; citation_author=M. K. Abe, K. T. Kahle, M. P. Saelzler, K. Orth, J. E. Dixon, M. R. Rosner; citation_volume=276; citation_publication_date=2001; citation_pages=21272-21279; citation_id=CR160

citation_journal_title=Pharmacol. Ther.; citation_title=The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors; citation_author=C. R. Weinstein-Oppenheimer, W. L. Blalock, L. S. Steelman, F. Chang, J. A. McCubrey; citation_volume=88; citation_publication_date=2000; citation_pages=229-279; citation_id=CR161

citation_journal_title=Oncogene; citation_title=Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2; citation_author=P. W. Janes, R. J. Daly, A. deFazio, R. L. Sutherland; citation_volume=9; citation_publication_date=1994; citation_pages=3601-3608; citation_id=CR162

citation_journal_title=Anticancer Res.; citation_title=Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer; citation_author=B. Salh, A. Marotta, C. Matthewson, M. Ahluwalia, J. Flint, D. Owen, S. Pelech; citation_volume=19; citation_publication_date=1999; citation_pages=731-740; citation_id=CR163

citation_journal_title=Endocr. Relat. Cancer; citation_title=Cyclooxygenase-2: A target for the prevention and treatment of breast cancer; citation_author=L. R. Howe, K. Subbaramaiah, A. M. Brown, A. J. Dannenberg; citation_volume=8; citation_publication_date=2001; citation_pages=97-114; citation_id=CR164

citation_journal_title=Mol. Pharmacol.; citation_title=Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor; citation_author=R. D. Nolan, R. M. Danilowicz, T. E. Eling; citation_volume=33; citation_publication_date=1988; citation_pages=650-656; citation_id=CR165

citation_journal_title=J. Biol. Chem.; citation_title=Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor; citation_author=G. K. Bandyopadhyay, W. Imagawa, D. Wallace, S. Nandi; citation_volume=262; citation_publication_date=1987; citation_pages=2750-2756; citation_id=CR166

citation_journal_title=FEBS Lett.; citation_title=Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or-2; citation_author=Y. Takahashi, F. Kawahara, M. Noguchi, K. Miwa, H. Sato, M. Seiki, H. Inoue, T. Tanabe, T. Yoshimoto; citation_volume=460; citation_publication_date=1999; citation_pages=145-148; citation_id=CR167

citation_journal_title=J. Natl. Cancer Inst.; citation_title=Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells; citation_author=P. H. Rolland, P. M. Martin, J. Jacquemier, A. M. Rolland, M. Toga; citation_volume=64; citation_publication_date=1980; citation_pages=1061-1070; citation_id=CR168

citation_journal_title=Int. J. Oncol.; citation_title=The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines; citation_author=E. M. Gilhooly, D. P. Rose; citation_volume=15; citation_publication_date=1999; citation_pages=267-270; citation_id=CR169

citation_journal_title=Cancer; citation_title=COX-2 is expressed in human pulmonary, colonic, and mammary tumors; citation_author=R. A. Soslow, A. J. Dannenberg, D. Rush, B. M. Woerner, K. N. Khan, J. Masferrer, A. T. Koki; citation_volume=89; citation_publication_date=2000; citation_pages=2637-2645; citation_id=CR170

citation_journal_title=Cancer Res.; citation_title=Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors; citation_author=J. L. Masferrer, K. M. Leahy, A. T. Koki, B. S. Zweifel, S. L. Settle, B. M. Woerner, D. A. Edwards, A. G. Flickinger, R. J. Moore, K. Seibert; citation_volume=60; citation_publication_date=2000; citation_pages=1306-1311; citation_id=CR171

citation_journal_title=Cancer Lett.; citation_title=Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas; citation_author=F. M. Robertson, M. L. Parrett, F. S. Joarder, M. Ross, H. M. Abou-Issa, G. Alshafie, R. E. Harris; citation_volume=122; citation_publication_date=1998; citation_pages=165-175; citation_id=CR172

citation_journal_title=Jpn. J. Cancer Res.; citation_title=Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats; citation_author=S. Nakatsugi, T. Ohta, T. Kawamori, M. Mutoh, T. Tanigawa, K. Watanabe, S. Sugie, T. Sugimura, K. Wakabayashi; citation_volume=91; citation_publication_date=2000; citation_pages=886-892; citation_id=CR173

citation_journal_title=Oncol. Rep.; citation_title=Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model; citation_author=G. A. Alshafie, H. M. Abou-Issa, K. Seibert, R. E. Harris; citation_volume=7; citation_publication_date=2000; citation_pages=1377-1381; citation_id=CR174

citation_journal_title=Cancer Res.; citation_title=Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor; citation_author=R. E. Harris, G. A. Alshafie, H. Abou-Issa, K. Seibert; citation_volume=60; citation_publication_date=2000; citation_pages=2101-2103; citation_id=CR175

citation_journal_title=Cancer Res.; citation_title=Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer; citation_author=L. R. Howe, K. Subbaramaiah, J. Patel, J. L. Masferrer, A. Deora, C. Hudis, H. T. Thaler, W. J. Muller, B. Du, A. M. Brown, A. J. Dannenberg; citation_volume=62; citation_publication_date=2002; citation_pages=5405-5407; citation_id=CR176

citation_journal_title=Anticancer Res.; citation_title=Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis; citation_author=H. M. Abou-Issa, G. A. Alshafie, K. Seibert, A. T. Koki, J. L. Masferrer, R. E. Harris; citation_volume=21; citation_publication_date=2001; citation_pages=3425-3432; citation_id=CR177

citation_journal_title=Drugs; citation_title=The second generation of COX-2 Inhibitors: What advantages do the newest offer?; citation_author=D. O. Stichtenoth, J. C. Frolich; citation_volume=63; citation_publication_date=2003; citation_pages=33-45; citation_id=CR178

citation_journal_title=Semin. Oncol.; citation_title=Docetaxel and exisulind in hormone-refractory prostate cancer; citation_author=C. W. Ryan, W. M. Stadler, N. J. Vogelzang; citation_volume=28; citation_publication_date=2001; citation_pages=56-61; citation_id=CR179

citation_journal_title=Curr. Opin. Investig. Drugs; citation_title=Exisulind cell pathways; citation_author=G. J. Griffiths; citation_volume=1; citation_publication_date=2000; citation_pages=386-391; citation_id=CR180

citation_journal_title=Semin. Oncol.; citation_title=Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer; citation_author=P. A. Bunn, D. C. Chan, K. Earle, T. L. Zhao, B. Helfrich, K. Kelly, G. Piazza, C. M. Whitehead, R. Pamukcu, W. Thompson, H. Alila; citation_volume=29; citation_publication_date=2002; citation_pages=87-94; citation_id=CR181

citation_journal_title=Oncologist; citation_title=ZD1839 (Iressa) in non-small cell lung cancer; citation_author=R. S. Herbst, M. S. Kies; citation_volume=7; citation_issue=Suppl4; citation_publication_date=2002; citation_pages=9-15; citation_id=CR182

citation_journal_title=Cancer Res.; citation_title=ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy; citation_author=A. E. Wakeling, S. P. Guy, J. R. Woodburn, S. E. Ashton, B. J. Curry, A. J. Barker, K. H. Gibson; citation_volume=62; citation_publication_date=2002; citation_pages=5749-5754; citation_id=CR183

C. Lu, C. Speers, Y. Zhang, X. Xu, J. Hill, E. Steinbis, J. Celestino, Q. Shen, H. Kim, S. G. Hilsenbeck, S. K. Mohsin, A. Wakeling, K. Osborne, and P. H. Brown (in press). The EGFR inhibitor ZD1839 (Gefitinib, “Iressa”) suppresses the development of estrogen receptor-negative mammary tumors in transgenic mice. J. Natl. Cancer Inst.

citation_journal_title=Trends Mol. Med.; citation_title=The ErbB receptor family: A therapeutic target for cancer; citation_author=J. S. de Bono, E. K. Rowinsky; citation_volume=8; citation_publication_date=2002; citation_pages=S19-S26; citation_id=CR185

citation_journal_title=Mol. Cancer Ther.; citation_title=Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma; citation_author=S. S. Ng, M. S. Tsao, T. Nicklee, D. W. Hedley; citation_volume=1; citation_publication_date=2002; citation_pages=777-783; citation_id=CR186

citation_journal_title=Oncology; citation_title=HER-targeted tyrosine-kinase inhibitors; citation_author=J. Baselga, L. A. Hammond; citation_volume=63; citation_issue=Suppl.1; citation_publication_date=2002; citation_pages=6-16; citation_id=CR187

citation_journal_title=Semin. Oncol.; citation_title=Epidermal growth factor receptor-targeted therapy for pancreatic cancer; citation_author=H. Q. Xiong, J. L. Abbruzzese; citation_volume=29; citation_publication_date=2002; citation_pages=31-37; citation_id=CR188

citation_journal_title=Semin. Oncol.; citation_title=Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer; citation_author=L. F. Allen, P. F. Lenehan, I. A. Eiseman, W. L. Elliott, D. W. Fry; citation_volume=29; citation_publication_date=2002; citation_pages=11-21; citation_id=CR189

citation_journal_title=Bioorg. Med. Chem. Lett.; citation_title=Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: Analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents; citation_author=A. Wissner, M. B. Brawner Floyd, S. K. Rabindran, R. Nilakantan, L. M. Greenberger, R. Shen, Y. F. Wang, H. R. Tsou; citation_volume=12; citation_publication_date=2002; citation_pages=2893-2897; citation_id=CR190

citation_journal_title=J. Clin. Oncol.; citation_title=Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types; citation_author=J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. G. Kieback, S. B. Kaye, L. Gianni, A. Harris, T. Bjork, S. D. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, J. Albanell; citation_volume=20; citation_publication_date=2002; citation_pages=4292-4302; citation_id=CR191

citation_journal_title=Anticancer Drugs; citation_title=Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033; citation_author=M. A. Gieseg, C. de Bock, L. R. Ferguson, W. A. Denny; citation_volume=12; citation_publication_date=2001; citation_pages=683-690; citation_id=CR192

citation_journal_title=Clin. Cancer Res.; citation_title=ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease; citation_author=R. J. Gilbertson, L. Bentley, R. Hernan, T. T. Junttila, A. J. Frank, H. Haapasalo, M. Connelly, C. Wetmore, T. Curran, K. Elenius, D. W. Ellison; citation_volume=8; citation_publication_date=2002; citation_pages=3054-3064; citation_id=CR193

citation_journal_title=Cancer Invest.; citation_title=Farnesyltransferase inhibitors in breast cancer therapy; citation_author=G. K. Dy, A. A. Adjei; citation_volume=20; citation_issue=Suppl2; citation_publication_date=2002; citation_pages=30-37; citation_id=CR194

citation_journal_title=Anticancer Drugs; citation_title=Farnesyl transferase inhibitors: A major breakthrough in anticancer therapy? Naples, 12 April 2002; citation_author=F. Caponigro; citation_volume=13; citation_publication_date=2002; citation_pages=891-897; citation_id=CR195

citation_journal_title=Semin. Hematol.; citation_title=Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of Zarnestra activity in high-risk leukemias; citation_author=J. E. Lancet, J. D. Rosenblatt, J. E. Karp; citation_volume=39; citation_publication_date=2002; citation_pages=31-35; citation_id=CR196

citation_journal_title=J. Clin. Oncol.; citation_title=Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer; citation_author=M. Crul, G. J. de Klerk, M. Swart, L. J. van't Veer, D. de Jong, L. Boerrigter, P. A. Palmer, C. J. Bol, H. Tan, G. C. de Gast, J. H. Beijnen, J. H. Schellens; citation_volume=20; citation_publication_date=2002; citation_pages=2726-2735; citation_id=CR197

citation_journal_title=Eur. J. Cancer; citation_title=Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours; citation_author=A. Awada, F. A. Eskens, M. Piccart, D. L. Cutler, A. van der Gaast, H. Bleiberg, J. Wanders, M. N. Faber, P. Statkevich, P. Fumoleau, J. Verweij; citation_volume=38; citation_publication_date=2002; citation_pages=2272-2278; citation_id=CR198

citation_journal_title=Clin. Cancer Res.; citation_title=Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis; citation_author=P. Norgaard, B. Law, H. Joseph, D. L. Page, Y. Shyr, D. Mays, J. A. Pietenpol, N. E. Kohl, A. Oliff, R. J. Coffey, H. S. Poulsen, H. L. Moses; citation_volume=5; citation_publication_date=1999; citation_pages=35-42; citation_id=CR199

citation_journal_title=Oncogene; citation_title=Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2; citation_author=R. A. Alcock, S. Dey, D. Chendil, M. S. Inayat, M. Mohiuddin, G. Hartman, L. K. Chatfield, V. S. Gallicchio, M. M. Ahmed; citation_volume=21; citation_publication_date=2002; citation_pages=7883-7890; citation_id=CR200

citation_journal_title=Prostate Cancer Prostatic Dis.; citation_title=Farnesyl: Protein transferase inhibitors as potential agents for the management of human prostate cancer; citation_author=L. Sepp-Lorenzino, G. Tjaden, M. M. Moasser, N. Timaul, Z. Ma, N. E. Kohl, J. B. Gibbs, A. Oliff, N. Rosen, H. I. Scher; citation_volume=4; citation_publication_date=2001; citation_pages=33-43; citation_id=CR201

citation_journal_title=Mol. Cancer Ther.; citation_title=Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor; citation_author=K. L. van Golen, L. Bao, M. M. DiVito, Z. Wu, G. C. Prendergast, S. D. Merajver; citation_volume=1; citation_publication_date=2002; citation_pages=575-583; citation_id=CR202

citation_journal_title=Semin. Radiat. Oncol.; citation_title=Farnesyltransferase inhibitors as radiation sensitizers; citation_author=W. G. McKenna, R. J. Muschel, A. K. Gupta, S. M. Hahn, E. J. Bernhard; citation_volume=12; citation_publication_date=2002; citation_pages=27-32; citation_id=CR203

citation_journal_title=Clin. Cancer Res.; citation_title=A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer; citation_author=S. M. Hahn, E. J. Bernhard, W. Regine, M. Mohiuddin, D. G. Haller, J. P. Stevenson, D. Smith, B. Pramanik, J. Tepper, T. F. DeLaney, K. D. Kiel, B. Morrison, P. Deutsch, R. J. Muschel, W. G. McKenna; citation_volume=8; citation_publication_date=2002; citation_pages=1065-1072; citation_id=CR204

citation_journal_title=Eur. J. Cancer; citation_title=XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase; citation_author=M. J. Donaldson, V. Skoumas, M. Watson, P. A. Ashworth, H. Ryder, M. Moore, R. C. Coombes; citation_volume=35; citation_publication_date=1999; citation_pages=1014-1019; citation_id=CR205

citation_journal_title=Endocr. Relat. Cancer; citation_title=Discovery of a novel Raf kinase inhibitor; citation_author=J. F. Lyons, S. Wilhelm, B. Hibner, G. Bollag; citation_volume=8; citation_publication_date=2001; citation_pages=219-225; citation_id=CR206

citation_journal_title=Curr. Pharm. Des.; citation_title=BAY 43-9006: early clinical data in patients with advanced solid malignancies; citation_author=S. J. Hotte, H. W. Hirte; citation_volume=8; citation_publication_date=2002; citation_pages=2249-2253; citation_id=CR207

citation_journal_title=Clin. Cancer Res.; citation_title=Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer; citation_author=C. M. Rudin, J. Holmlund, G. F. Fleming, S. Mani, W. M. Stadler, P. Schumm, B. P. Monia, J. F. Johnston, R. Geary, R. Z. Yu, T. J. Kwoh, F. A. Dorr, M. J. Ratain; citation_volume=7; citation_publication_date=2001; citation_pages=1214-1220; citation_id=CR208

citation_journal_title=Clin. Cancer Res.; citation_title=A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer; citation_author=A. W. Tolcher, L. Reyno, P. M. Venner, S. D. Ernst, M. Moore, R. S. Geary, K. Chi, S. Hall, W. Walsh, A. Dorr, E. Eisenhauer; citation_volume=8; citation_publication_date=2002; citation_pages=2530-2535; citation_id=CR209

citation_journal_title=Clin. Cancer Res.; citation_title=Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada clinical trials group study; citation_author=M. C. Cripps, A. T. Figueredo, A. M. Oza, M. J. Taylor, A. L. Fields, J. T. Holmlund, L. W. McIntosh, R. S. Geary, E. A. Eisenhauer; citation_volume=8; citation_publication_date=2002; citation_pages=2188-2192; citation_id=CR210

citation_journal_title=Eur. J. Cancer; citation_title=Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report; citation_author=B. Coudert, A. Anthoney, W. Fiedler, J. P. Droz, V. Dieras, M. Borner, J. F. Smyth, R. Morant, M. J. de Vries, M. Roelvink, P. Fumoleau; citation_volume=37; citation_publication_date=2001; citation_pages=2194-2198; citation_id=CR211

citation_journal_title=Cancer Chemother. Pharmacol.; citation_title=Stereospecific antitumor activity of radicicol oxime derivatives; citation_author=S. Soga, S. V. Sharma, Y. Shiotsu, M. Shimizu, H. Tahara, K. Yamaguchi, Y. Ikuina, C. Murakata, T. Tamaoki, J. Kurebayashi, T. W. Schulte, L. M. Neckers, S. Akinaga; citation_volume=48; citation_publication_date=2001; citation_pages=435-445; citation_id=CR212

citation_journal_title=Oncogene; citation_title=Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2; citation_author=A. D. Basso, D. B. Solit, P. N. Munster, N. Rosen; citation_volume=21; citation_publication_date=2002; citation_pages=1159-1166; citation_id=CR213

citation_journal_title=Mol. Cancer Ther.; citation_title=Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells; citation_author=A. S. Clark, K. West, S. Streicher, P. A. Dennis; citation_volume=1; citation_publication_date=2002; citation_pages=707-717; citation_id=CR214

citation_journal_title=J. Natl. Cancer Inst.; citation_title=Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts; citation_author=F. Wang, R. K. Hansen, D. Radisky, T. Yoneda, M. H. Barcellos-Hoff, O. W. Petersen, E. A. Turley, M. J. Bissell; citation_volume=94; citation_publication_date=2002; citation_pages=1494-1503; citation_id=CR215

citation_journal_title=Clin. Cancer Res.; citation_title=Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma; citation_author=S. Semba, N. Itoh, M. Ito, E. M. Youssef, M. Harada, T. Moriya, W. Kimura, M. Yamakawa; citation_volume=8; citation_publication_date=2002; citation_pages=3824-3831; citation_id=CR216

citation_journal_title=Jpn. J. Cancer Res.; citation_title=Differential mechanisms of constitutive Akt/PKB activation and its influence on gene expression in pancreatic cancer cells; citation_author=J. Matsumoto, M. Kaneda, M. Tada, J. Hamada, S. Okushiba, S. Kondo, H. Katoh, T. Moriuchi; citation_volume=93; citation_publication_date=2002; citation_pages=1317-1326; citation_id=CR217

citation_journal_title=Cancer Res.; citation_title=PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death; citation_author=L. P. Weng, W. M. Smith, P. L. Dahia, U. Ziebold, E. Gil, J. A. Lees, C. Eng; citation_volume=59; citation_publication_date=1999; citation_pages=5808-5814; citation_id=CR218

citation_journal_title=J. Cell. Physiol.; citation_title=Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells; citation_author=T. G. Ram, H. L. Hosick, S. P. Ethier; citation_volume=183; citation_publication_date=2000; citation_pages=301-313; citation_id=CR219

citation_journal_title=Cell Growth Differ.; citation_title=Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation; citation_author=U. Hermanto, C. S. Zong, L. H. Wang; citation_volume=11; citation_publication_date=2000; citation_pages=655-664; citation_id=CR220

citation_journal_title=Gut; citation_title=Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells; citation_author=R. Jaster, G. Sparmann, J. Emmrich, S. Liebe; citation_volume=51; citation_publication_date=2002; citation_pages=579-584; citation_id=CR221

citation_journal_title=Biochem. Biophys. Res. Commun.; citation_title=ERK1/2 mediates PDGF-BB stimulated vascular smooth muscle cell proliferation and migration on laminin-5; citation_author=K. Kingsley, J. L. Huff, W. L. Rust, K. Carroll, A. M. Martinez, M. Fitchmun, G. E. Plopper; citation_volume=293; citation_publication_date=2002; citation_pages=1000-1006; citation_id=CR222

citation_journal_title=Faseb J; citation_title=MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b; citation_author=F. Romerio, D. Zella; citation_volume=16; citation_publication_date=2002; citation_pages=1680-1682; citation_id=CR223

citation_journal_title=J. Immunol.; citation_title=Differential roles for extracellularly regulated kinase-mitogen-activated protein kinase in B cell antigen receptor-induced apoptosis and CD40-mediated rescue of WEHI-231 immature B cells; citation_author=S. B. Gauld, D. Blair, C. A. Moss, S. D. Reid, M. M. Harnett; citation_volume=168; citation_publication_date=2002; citation_pages=3855-3864; citation_id=CR224

citation_journal_title=J. Cell Biochem.; citation_title=Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival; citation_author=H. Xin, Y. Geng, R. Pramanik, D. Choubey; citation_volume=88; citation_publication_date=2003; citation_pages=191-204; citation_id=CR225

citation_journal_title=Nat. Med.; citation_title=Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo; citation_author=J. S. Sebolt-Leopold, D. T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, R. C. Gowan, H. Tecle, S. D. Barrett, A. Bridges, S. Przybranowski, W. R. Leopold, A. R. Saltiel; citation_volume=5; citation_publication_date=1999; citation_pages=810-816; citation_id=CR226

citation_journal_title=Biochem. Pharmacol.; citation_title=Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated CYP1A1 and CYP1B1 induction by 12-O-tetradecanoylphorbol-13-acetate: Role of transforming growth factor beta and mitogen-activated protein kinases; citation_author=M. Guo, A. Joiakim, D. T. Dudley, J. J. Reiners; citation_volume=62; citation_publication_date=2001; citation_pages=1449-1457; citation_id=CR227

citation_journal_title=Cytometry; citation_title=Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors; citation_author=S. Chow, H. Patel, D. W. Hedley; citation_volume=46; citation_publication_date=2001; citation_pages=72-78; citation_id=CR228

citation_journal_title=Bioorg. Med. Chem. Lett.; citation_title=MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines; citation_author=N. Zhang, B. Wu, N. Eudy, Y. Wang, F. Ye, D. Powell, A. Wissner, L. R. Feldberg, S. C. Kim, R. Mallon, E. D. Kovacs, L. Toral-Barza, C. A. Kohler; citation_volume=11; citation_publication_date=2001; citation_pages=1407-1410; citation_id=CR229

citation_journal_title=Bioorg. Med. Chem. Lett.; citation_title=4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors; citation_author=N. Zhang, B. Wu, A. Wissner, D. W. Powell, S. K. Rabindran, C. Kohler, F. Boschelli; citation_volume=12; citation_publication_date=2002; citation_pages=423-425; citation_id=CR230

citation_journal_title=Bioorg. Med. Chem. Lett.; citation_title=Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors; citation_author=N. Zhang, B. Wu, D. Powell, A. Wissner, M. B. Floyd, E. D. Kovacs, L. Toral-Barza, C. Kohler; citation_volume=10; citation_publication_date=2000; citation_pages=2825-2828; citation_id=CR231

citation_journal_title=Infect. Immun.; citation_title=Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway; citation_author=T. van der Bruggen, S. Nijenhuis, E. van Raaij, J. Verhoef, B. S. van Asbeck; citation_volume=67; citation_publication_date=1999; citation_pages=3824-3829; citation_id=CR232

citation_journal_title=J. Antibiot. (Tokyo); citation_title=Resorcylic acid lactones: Naturally occurring potent and selective inhibitors of MEK; citation_author=A. Zhao, S. H. Lee, M. Mojena, R. G. Jenkins, D. R. Patrick, H. E. Huber, M. A. Goetz, O. D. Hensens, D. L. Zink, D. Vilella, A. W. Dombrowski, R. B. Lingham, L. Huang; citation_volume=52; citation_publication_date=1999; citation_pages=1086-1094; citation_id=CR233

citation_journal_title=Biochem. Biophys. Res. Commun.; citation_title=A radicicol-related macrocyclic nonaketide compound, antibiotic LL-Z1640-2, inhibits the JNK/p38 pathways in signal-specific manner; citation_author=K. Takehana, S. Sato, T. Kobayasi, T. Maeda; citation_volume=257; citation_publication_date=1999; citation_pages=19-23; citation_id=CR234

citation_journal_title=Arch. Biochem. Biophys.; citation_title=The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway; citation_author=B. Sanna, M. Debidda, G. Pintus, B. Tadolini, A. M. Posadino, F. Bennardini, G. Sava, C. Ventura; citation_volume=403; citation_publication_date=2002; citation_pages=209-218; citation_id=CR235

citation_journal_title=Biochemistry; citation_title=Competitive inhibition of MAP kinase activation by a peptide representing the alpha C helix of ERK; citation_author=K. Y. Horiuchi, P. A. Scherle, J. M. Trzaskos, R. A. Copeland; citation_volume=37; citation_publication_date=1998; citation_pages=8879-8885; citation_id=CR236

citation_journal_title=Cancer Res.; citation_title=Regulation by p38 mitogen-activated protein kinase of adenylate-and uridylate-rich element-mediated urokinase-type plasminogen activator (uPA) messenger RNA stability and uPA-dependent in vitro cell invasion; citation_author=L. Montero, Y. Nagamine; citation_volume=59; citation_publication_date=1999; citation_pages=5286-5293; citation_id=CR237

citation_journal_title=J. Biol. Chem.; citation_title=Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway; citation_author=P. W. Tsai, S. G. Shiah, M. T. Lin, C. W. Wu, M. L. Kuo; citation_volume=278; citation_publication_date=2003; citation_pages=5750-5759; citation_id=CR238

citation_journal_title=Expert Opin. Ther. Pat.; citation_title=new inhibitors of p38 kinase; citation_author=J. C. Boehm, J. L. Adams; citation_volume=10; citation_publication_date=2000; citation_pages=25-37; citation_id=CR239

citation_journal_title=Immunopharmacology; citation_title=Inhibition of p38 MAP kinase as a therapeutic strategy; citation_author=J. C. Lee, S. Kumar, D. E. Griswold, D. C. Underwood, B. J. Votta, J. L. Adams; citation_volume=47; citation_publication_date=2000; citation_pages=185-201; citation_id=CR240

citation_journal_title=Prog. Med. Chem.; citation_title=Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases; citation_author=M. S. Saporito, R. L. Hudkins, A. C. Maroney; citation_volume=40; citation_publication_date=2002; citation_pages=23-62; citation_id=CR241

citation_journal_title=J. Clin. Invest.; citation_title=c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis; citation_author=Z. Han, D. L. Boyle, L. Chang, B. Bennett, M. Karin, L. Yang, A. M. Manning, G. S. Firestein; citation_volume=108; citation_publication_date=2001; citation_pages=73-81; citation_id=CR242

citation_journal_title=Proc. Natl. Acad. Sci. U. S. A.; citation_title=SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase; citation_author=B. L. Bennett, D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S. S. Bhagwat, A. M. Manning, D. W. Anderson; citation_volume=98; citation_publication_date=2001; citation_pages=13681-13686; citation_id=CR243

citation_journal_title=Anticancer Res.; citation_title=Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis; citation_author=H. M. Abou-Issa, G. A. Alshafie, K. Seibert, A. T. Koki, J. L. Masferrer, R. E. Harris; citation_volume=21; citation_publication_date=2001; citation_pages=3425-3432; citation_id=CR244

citation_journal_title=Cancer Res.; citation_title=The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells; citation_author=M. M. Moasser, A. Basso, S. D. Averbuch, N. Rosen; citation_volume=61; citation_publication_date=2001; citation_pages=7184-7188; citation_id=CR245

citation_journal_title=Oncogene; citation_title=The EGF receptor family as targets for cancer therapy; citation_author=J. Mendelsohn, J. Baselga; citation_volume=19; citation_publication_date=2000; citation_pages=6550-6565; citation_id=CR246

citation_journal_title=Curr. Opin. Oncol.; citation_title=Inhibitors of tyrosine kinase; citation_author=W. D. Klohs, D. W. Fry, A. J. Kraker; citation_volume=9; citation_publication_date=1997; citation_pages=562-568; citation_id=CR247

citation_journal_title=Cancer Res.; citation_title=Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo; citation_author=S. L. Moulder, F. M. Yakes, S. K. Muthuswamy, R. Bianco, J. F. Simpson, C. L. Arteaga; citation_volume=61; citation_publication_date=2001; citation_pages=8887-8895; citation_id=CR248

citation_journal_title=Cancer Res.; citation_title=Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast; citation_author=K. C. Chan, W. F. Knox, J. M. Gee, J. Morris, R. I. Nicholson, C. S. Potten, N. J. Bundred; citation_volume=62; citation_publication_date=2002; citation_pages=122-128; citation_id=CR249

citation_journal_title=Breast Cancer Res. Treat.; citation_title=A phase II study of ZD1839 (“Iressa”) in tamoxifen-resistant ER-positive and endocrine-insensitive (ER-negative) breast cancer; citation_author=J. F. R. Robertson, E. Gutteridge, K. L. Cheung, R. Owers, M. Koehler, L. Hamilton; citation_volume=76; citation_publication_date=2002; citation_pages=S96; citation_id=CR250

citation_journal_title=Breast Cancer Res. Treat.; citation_title=Open-label, phase II, multicenter trial of ZD1839 (“Iressa”) in patients with advanced breast cancer; citation_author=K. Albain, R. Ellege, W. J. Gradishar, D. F. Hayes, E. Rowinsky, C. Hudis, L. Pusztai, D. Tripathy, S. Modi, S. Rubi; citation_volume=76; citation_publication_date=2002; citation_pages=S33; citation_id=CR251

citation_journal_title=Cancer Res.; citation_title=Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase; citation_author=J. D. Moyer, E. G. Barbacci, K. K. Iwata, L. Arnold, B. Boman, A. Cunningham, C. DiOrio, J. Doty, M. J. Morin, M. P. Moyer, M. Neveu, V. A. Pollack, L. R. Pustilnik, M. M. Reynolds, D. Sloan, A. Theleman, P. Miller; citation_volume=57; citation_publication_date=1997; citation_pages=4838-4848; citation_id=CR252

citation_journal_title=J. Pharmacol. Exp. Ther.; citation_title=Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice; citation_author=V. A. Pollack, D. M. Savage, D. A. Baker, K. E. Tsaparikos, D. E. Sloan, J. D. Moyer, E. G. Barbacci, L. R. Pustilnik, T. A. Smolarek, J. A. Davis, M. P. Vaidya, L. D. Arnold, J. L. Doty, K. K. Iwata, M. J. Morin; citation_volume=291; citation_publication_date=1999; citation_pages=739-748; citation_id=CR253

citation_journal_title=Clin. Cancer Res.; citation_title=Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma; citation_author=C. C. Solorzano, C. H. Baker, R. Tsan, P. Traxler, P. Cohen, E. Buchdunger, J. J. Killion, I. J. Fidler; citation_volume=7; citation_publication_date=2001; citation_pages=2563-2572; citation_id=CR254

citation_journal_title=Cancer Res.; citation_title=Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer; citation_author=C. H. Baker, C. C. Solorzano, I. J. Fidler; citation_volume=62; citation_publication_date=2002; citation_pages=1996-2003; citation_id=CR255

citation_journal_title=Oncogene; citation_title=Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents; citation_author=R. Brandt, A. M. Wong, N. E. Hynes; citation_volume=20; citation_publication_date=2001; citation_pages=5459-5465; citation_id=CR256

citation_journal_title=J. Med. Chem.; citation_title=Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor; citation_author=J. B. Smaill, H. D. Showalter, H. Zhou, A. J. Bridges, D. J. McNamara, D. W. Fry, J. M. Nelson, V. Sherwood, P. W. Vincent, B. J. Roberts, W. L. Elliott, W. A. Denny; citation_volume=44; citation_publication_date=2001; citation_pages=429-440; citation_id=CR257

citation_journal_title=Int. J. Radiat. Oncol. Biol. Phys.; citation_title=Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor; citation_author=G. S. Rao, S. Murray, S. P. Ethier; citation_volume=48; citation_publication_date=2000; citation_pages=1519-1528; citation_id=CR258

citation_journal_title=Mol. Cancer Ther.; citation_title=The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo; citation_author=D. W. Rusnak, K. Lackey, K. Affleck, E. R. Wood, K. J. Alligood, N. Rhodes, B. R. Keith, D. M. Murray, W. B. Knight, R. J. Mullin, T. M. Gilmer; citation_volume=1; citation_publication_date=2001; citation_pages=85-94; citation_id=CR259

citation_journal_title=Endocr. Relat. Cancer; citation_title=Farnesyl transferase inhibitors–a novel therapy for breast cancer; citation_author=S. R. Johnston, L. R. Kelland; citation_volume=8; citation_publication_date=2001; citation_pages=227-235; citation_id=CR260

citation_journal_title=J. Immunother.; citation_title=A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors; citation_author=S. N. Khleif, S. I. Abrams, J. M. Hamilton, E. Bergmann-Leitner, A. Chen, A. Bastian, S. Bernstein, Y. Chung, C. J. Allegra, J. Schlom; citation_volume=22; citation_publication_date=1999; citation_pages=155-165; citation_id=CR261

citation_journal_title=Breast Cancer Res. Treat.; citation_title=Ras activation in human breast cancer; citation_author=F. C. von Lintig, A. D. Dreilinger, N. M. Varki, A. M. Wallace, D. E. Casteel, G. R. Boss; citation_volume=62; citation_publication_date=2000; citation_pages=51-62; citation_id=CR262

citation_journal_title=J. Mam. Gland Biol. Neoplasia; citation_title=The ras signaling pathway in mammary tumorigenesis and metastasis; citation_author=S. Malaney, R. J. Daly; citation_volume=6; citation_publication_date=2001; citation_pages=101-113; citation_id=CR263

citation_journal_title=Jpn. J. Cancer Res.; citation_title=Mammary carcinomas induced in human c-Ha-ras proto-oncogene transgenic rats are estrogen-independent, but responsive to d-limonene treatment; citation_author=M. Asamoto, T. Ota, H. Toriyama-Baba, N. Hokaiwado, A. Naito, H. Tsuda; citation_volume=93; citation_publication_date=2002; citation_pages=32-35; citation_id=CR264

citation_journal_title=Breast Cancer Res.; citation_title=Inducible transgenics. New lessons on events governing the induction and commitment in mammary tumorigenesis; citation_author=J. Hulit, D. Di Vizio, R. G. Pestell; citation_volume=3; citation_publication_date=2001; citation_pages=209-212; citation_id=CR265

citation_journal_title=Cancer Res.; citation_title=Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro; citation_author=D. W. End, G. Smets, A. V. Todd, T. L. Applegate, C. J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, A. Devine, W. Wouters, C. Bowden; citation_volume=61; citation_publication_date=2001; citation_pages=131-137; citation_id=CR266

citation_journal_title=Clin. Cancer Res.; citation_title=Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer; citation_author=L. R. Kelland, V. Smith, M. Valenti, L. Patterson, P. A. Clarke, S. Detre, D. End, A. J. Howes, M. Dowsett, P. Workman, S. R. Johnston; citation_volume=7; citation_publication_date=2001; citation_pages=3544-3550; citation_id=CR267

citation_journal_title=Ann. Oncol.; citation_title=Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units; citation_author=T. Petit, E. Izbicka, R. A. Lawrence, W. R. Bishop, S. Weitman, D. D. Von Hoff; citation_volume=10; citation_publication_date=1999; citation_pages=449-453; citation_id=CR268

citation_journal_title=Cancer Res.; citation_title=Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor; citation_author=W. C. Rose, F. Y. Lee, C. R. Fairchild, M. Lynch, T. Monticello, R. A. Kramer, V. Manne; citation_volume=61; citation_publication_date=2001; citation_pages=7507-7517; citation_id=CR269

citation_journal_title=Semin. Hematol.; citation_title=Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome; citation_author=R. Kurzrock, J. Cortes, H. Kantarjian; citation_volume=39; citation_publication_date=2002; citation_pages=20-24; citation_id=CR270

citation_journal_title=Anal. Biochem.; citation_title=High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123; citation_author=C. A. Buser, C. J. Dinsmore, C. Fernandes, I. Greenberg, K. Hamilton, S. D. Mosser, E. S. Walsh, T. M. Williams, K. S. Koblan; citation_volume=290; citation_publication_date=2001; citation_pages=126-137; citation_id=CR271

citation_journal_title=Breast Cancer Res. Treat.; citation_title=Farnesyltransferase inhibitors and anti-Ras therapy; citation_author=J. B. Gibbs, N. E. Kohl, K. S. Koblan, C. A. Omer, L. Sepp-Lorenzino, N. Rosen, N. J. Anthony, M. W. Conner, S. J. deSolms, T. M. Williams, S. L. Graham, G. D. Hartman, A. Oliff; citation_volume=38; citation_publication_date=1996; citation_pages=75-83; citation_id=CR272

citation_journal_title=Cancer Biol. Ther.; citation_title=The Effects of beta-Estradiol on Raf Activity, Cell Cycle Progression and Growth Factor Synthesis in the MCF-7 Breast Cancer Cell Line; citation_author=C. R. Weinstein-Oppenheimer, C. Burrows, L. S. Steelman, J. A. McCubrey; citation_volume=1; citation_publication_date=2002; citation_pages=256-262; citation_id=CR273

citation_journal_title=Oncology; citation_title=Mitogen-activated protein kinase cascade in breast cancer; citation_author=M. Maemura, Y. Iino, Y. Koibuchi, T. Yokoe, Y. Morishita; citation_volume=57; citation_issue=Suppl2; citation_publication_date=1999; citation_pages=37-44; citation_id=CR274

citation_journal_title=Br. J. Cancer; citation_title=Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer; citation_author=F. McPhillips, P. Mullen, B. P. Monia, A. A. Ritchie, F. A. Dorr, J. F. Smyth, S. P. Langdon; citation_volume=85; citation_publication_date=2001; citation_pages=1753-1758; citation_id=CR275

citation_journal_title=Clin. Cancer Res.; citation_title=c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A); citation_author=P. J. O'Dwyer, J. P. Stevenson, M. Gallagher, A. Cassella, I. Vasilevskaya, B. P. Monia, J. Holmlund, F. A. Dorr, K. S. Yao; citation_volume=5; citation_publication_date=1999; citation_pages=3977-3982; citation_id=CR276

citation_journal_title=Trends Mol. Med.; citation_title=Hsp90 inhibitors as novel cancer chemotherapeutic agents; citation_author=L. Neckers; citation_volume=8; citation_publication_date=2002; citation_pages=S55-S61; citation_id=CR277

citation_journal_title=Mol. Cell. Biol.; citation_title=Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway; citation_author=T. W. Schulte, M. V. Blagosklonny, L. Romanova, J. F. Mushinski, B. P. Monia, J. F. Johnston, P. Nguyen, J. Trepel, L. M. Neckers; citation_volume=16; citation_publication_date=1996; citation_pages=5839-5845; citation_id=CR278

citation_journal_title=J. Biol. Chem.; citation_title=Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association; citation_author=T. W. Schulte, M. V. Blagosklonny, C. Ingui, L. Neckers; citation_volume=270; citation_publication_date=1995; citation_pages=24585-24588; citation_id=CR279

citation_journal_title=Proc. Natl. Acad. Sci. U. S. A.; citation_title=Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu; citation_author=W. Xu, M. Marcu, X. Yuan, E. Mimnaugh, C. Patterson, L. Neckers; citation_volume=99; citation_publication_date=2002; citation_pages=12847-12852; citation_id=CR280

citation_journal_title=Biochemistry (Mosc); citation_title=Phosphatidylinositol-3 kinase dependent pathways: The role in control of cell growth, survival, and malignant transformation; citation_author=M. A. Krasilnikov; citation_volume=65; citation_publication_date=2000; citation_pages=59-67; citation_id=CR281

citation_journal_title=Annu. Rev. Cell Dev. Biol.; citation_title=Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer; citation_author=R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, M. D. Waterfield; citation_volume=17; citation_publication_date=2001; citation_pages=615-675; citation_id=CR282

citation_journal_title=Nat. Rev. Cancer; citation_title=The phosphatidylinositol 3-Kinase AKT pathway in human cancer; citation_author=I. Vivanco, C. L. Sawyers; citation_volume=2; citation_publication_date=2002; citation_pages=489-501; citation_id=CR283

citation_journal_title=Nature; citation_title=Oncogenic kinase signalling; citation_author=P. Blume-Jensen, T. Hunter; citation_volume=411; citation_publication_date=2001; citation_pages=355-365; citation_id=CR284

citation_journal_title=Genes Dev.; citation_title=Cellular survival: A play in three Akts; citation_author=S. R. Datta, A. Brunet, M. E. Greenberg; citation_volume=13; citation_publication_date=1999; citation_pages=2905-2927; citation_id=CR285

citation_journal_title=Mol. Cell. Biol.; citation_title=Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression; citation_author=J. Hutchinson, J. Jin, R. D. Cardiff, J. R. Woodgett, W. J. Muller; citation_volume=21; citation_publication_date=2001; citation_pages=2203-2212; citation_id=CR286

citation_journal_title=Nature; citation_title=Direct control of the Forkhead transcription factor AFX by protein kinase B; citation_author=G. J. Kops, N. D. de Ruiter, A. M. De Vries-Smits, D. R. Powell, J. L. Bos, B. M. Burgering; citation_volume=398; citation_publication_date=1999; citation_pages=630-634; citation_id=CR287

citation_journal_title=Nat. Cell Biol.; citation_title=Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells; citation_author=B. P. Zhou, Y. Liao, W. Xia, B. Spohn, M. H. Lee, M. C. Hung; citation_volume=3; citation_publication_date=2001; citation_pages=245-252; citation_id=CR288

citation_journal_title=Nature; citation_title=AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1; citation_author=R. H. Medema, G. J. Kops, J. L. Bos, B. M. Burgering; citation_volume=404; citation_publication_date=2000; citation_pages=782-787; citation_id=CR289

citation_journal_title=Cancer Res.; citation_title=Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K; citation_author=M. Sun, J. E. Paciga, R. I. Feldman, Z. Yuan, D. Coppola, Y. Y. Lu, S. A. Shelley, S. V. Nicosia, J. Q. Cheng; citation_volume=61; citation_publication_date=2001; citation_pages=5985-5991; citation_id=CR290

citation_journal_title=Am. J. Pathol.; citation_title=AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells; citation_author=M. Sun, G. Wang, J. E. Paciga, R. I. Feldman, Z. Q. Yuan, X. L. Ma, S. A. Shelley, R. Jove, P. N. Tsichlis, S. V. Nicosia, J. Q. Cheng; citation_volume=159; citation_publication_date=2001; citation_pages=431-437; citation_id=CR291

citation_journal_title=Nat. Genet.; citation_title=PIK3CA is implicated as an oncogene in ovarian cancer; citation_author=L. Shayesteh, Y. Lu, W. L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G. B. Mills, J. W. Gray; citation_volume=21; citation_publication_date=1999; citation_pages=99-102; citation_id=CR292

citation_journal_title=Cancer Res.; citation_title=The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors; citation_author=A. J. Philp, I. G. Campbell, C. Leet, E. Vincan, S. P. Rockman, R. H. Whitehead, R. J. Thomas, W. A. Phillips; citation_volume=61; citation_publication_date=2001; citation_pages=7426-7429; citation_id=CR293

citation_journal_title=Cancer Res.; citation_title=Overexpression and overactivation of Akt in thyroid carcinoma; citation_author=M. D. Ringel, N. Hayre, J. Saito, B. Saunier, F. Schuppert, H. Burch, V. Bernet, K. D. Burman, L. D. Kohn, M. Saji; citation_volume=61; citation_publication_date=2001; citation_pages=6105-6111; citation_id=CR294

citation_journal_title=J. Biol. Chem.; citation_title=Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice; citation_author=H. Cho, J. L. Thorvaldsen, Q. Chu, F. Feng, M. J. Birnbaum; citation_volume=276; citation_publication_date=2001; citation_pages=38349-38352; citation_id=CR295

citation_journal_title=Cancer Res.; citation_title=High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice; citation_author=V. Stambolic, M. S. Tsao, D. Macpherson, A. Suzuki, W. B. Chapman, T. W. Mak; citation_volume=60; citation_publication_date=2000; citation_pages=3605-3611; citation_id=CR296

citation_journal_title=Mol. Endocrinol.; citation_title=Mammary gland involution is delayed by activated Akt in transgenic mice; citation_author=K. L. Schwertfeger, M. M. Richert, S. M. Anderson; citation_volume=15; citation_publication_date=2001; citation_pages=867-881; citation_id=CR297

citation_journal_title=J. Biol. Chem.; citation_title=Regulation of Raf-Akt Cross-talk; citation_author=K. Moelling, K. Schad, M. Bosse, S. Zimmermann, M. Schweneker; citation_volume=277; citation_publication_date=2002; citation_pages=31099-31106; citation_id=CR298

citation_journal_title=Immunol. Today; citation_title=PI 3-kinase: A pivotal pathway in T-cell activation?; citation_author=S. G. Ward, C. H. June, D. Olive; citation_volume=17; citation_publication_date=1996; citation_pages=187-197; citation_id=CR299

citation_journal_title=J. Biol. Chem.; citation_title=A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002); citation_author=C. J. Vlahos, W. F. Matter, K. Y. Hui, R. F. Brown; citation_volume=269; citation_publication_date=1994; citation_pages=5241-5248; citation_id=CR300

citation_journal_title=J. Biol. Chem.; citation_title=Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration; citation_author=A. V. Bakin, A. K. Tomlinson, N. A. Bhowmick, H. L. Moses, C. L. Arteaga; citation_volume=275; citation_publication_date=2000; citation_pages=36803-36810; citation_id=CR301

citation_journal_title=Mol. Cell. Biol.; citation_title=Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction; citation_author=M. P. Wymann, G. Bulgarelli-Leva, M. J. Zvelebil, L. Pirola, B. Vanhaesebroeck, M. D. Waterfield, G. Panayotou; citation_volume=16; citation_publication_date=1996; citation_pages=1722-1733; citation_id=CR302

citation_journal_title=Cell Growth Differ.; citation_title=Constitutively active mitogen-activated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses; citation_author=S. J. Mansour, J. M. Candia, K. K. Gloor, N. G. Ahn; citation_volume=7; citation_publication_date=1996; citation_pages=243-250; citation_id=CR303

citation_journal_title=J. Biol. Chem.; citation_title=Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells; citation_author=J. C. Donovan, A. Milic, J. M. Slingerland; citation_volume=276; citation_publication_date=2001; citation_pages=40888-40895; citation_id=CR304

citation_journal_title=Cancer Res.; citation_title=MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition; citation_author=J. Pinkas, P. Leder; citation_volume=62; citation_publication_date=2002; citation_pages=4781-4790; citation_id=CR305

citation_journal_title=J. Biol. Chem.; citation_title=Identification of a novel inhibitor of mitogen-activated protein kinase kinase; citation_author=M. F. Favata, K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, R. A. Copeland, R. L. Magolda, P. A. Scherle, J. M. Trzaskos; citation_volume=273; citation_publication_date=1998; citation_pages=18623-18632; citation_id=CR306

citation_journal_title=Cell Growth Differ.; citation_title=Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis; citation_author=E. K. Lobenhofer, G. Huper, J. D. Iglehart, J. R. Marks; citation_volume=11; citation_publication_date=2000; citation_pages=99-110; citation_id=CR307

citation_journal_title=Breast Cancer Res. Treat.; citation_title=Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer; citation_author=Y. Hu, W. H. Dragowska, A. Wallis, V. Duronio, L. Mayer; citation_volume=70; citation_publication_date=2001; citation_pages=11-20; citation_id=CR308

citation_journal_title=Mol. Cancer Ther.; citation_title=Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway; citation_author=H. Fukazawa, K. Noguchi, Y. Murakami, Y. Uehara; citation_volume=1; citation_publication_date=2002; citation_pages=303-309; citation_id=CR309

citation_journal_title=Biochem. J.; citation_title=Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1; citation_author=M. S. Squires, P. M. Nixon, S. J. Cook; citation_volume=366; citation_publication_date=2002; citation_pages=673-680; citation_id=CR310

citation_journal_title=Biochem. J.; citation_title=Specificity and mechanism of action of some commonly used protein kinase inhibitors; citation_author=S. P. Davies, H. Reddy, M. Caivano, P. Cohen; citation_volume=351; citation_publication_date=2000; citation_pages=95-105; citation_id=CR311

citation_journal_title=Oncogene; citation_title=Development of anticancer drugs targeting the MAP kinase pathway; citation_author=J. S. Sebolt-Leopold; citation_volume=19; citation_publication_date=2000; citation_pages=6594-6599; citation_id=CR312

citation_journal_title=J. Clin. Invest.; citation_title=Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia; citation_author=M. Milella, S. M. Kornblau, Z. Estrov, B. Z. Carter, H. Lapillonne, D. Harris, M. Konopleva, S. Zhao, E. Estey, M. Andreeff; citation_volume=108; citation_publication_date=2001; citation_pages=851-859; citation_id=CR313

citation_journal_title=Biochemistry; citation_title=Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity; citation_author=D. H. Williams, S. E. Wilkinson, T. Purton, A. Lamont, H. Flotow, E. J. Murray; citation_volume=37; citation_publication_date=1998; citation_pages=9579-9585; citation_id=CR314

citation_journal_title=Biochem. Soc. Symp.; citation_title=Making the connection: Coupling of stress-activated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signalling modules to extracellular stimuli and biological responses; citation_author=J. M. Kyriakis; citation_volume=64; citation_publication_date=1999; citation_pages=29-48; citation_id=CR315

citation_journal_title=Oral Oncol.; citation_title=Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma; citation_author=K. Mishima, K. Inoue, Y. Hayashi; citation_volume=38; citation_publication_date=2002; citation_pages=468-474; citation_id=CR316

citation_journal_title=Dig. Dis. Sci.; citation_title=Analysis of signaling protein kinases in human colon or colorectal carcinomas; citation_author=L. L. Licato, D. A. Brenner; citation_volume=43; citation_publication_date=1998; citation_pages=1454-1464; citation_id=CR317

citation_journal_title=Oncogene; citation_title=Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors; citation_author=R. Hoshino, Y. Chatani, T. Yamori, T. Tsuruo, H. Oka, O. Yoshida, Y. Shimada, S. Ari-i, H. Wada, J. Fujimoto, M. Kohno; citation_volume=18; citation_publication_date=1999; citation_pages=813-822; citation_id=CR318

citation_journal_title=J. Steroid Biochem. Mol. Biol.; citation_title=The role of mitogen-activated protein (MAP) kinase in breast cancer; citation_author=R. J. Santen, R. X. Song, R. McPherson, R. Kumar, L. Adam, M. H. Jeng, W. Yue; citation_volume=80; citation_publication_date=2002; citation_pages=239-256; citation_id=CR319

citation_journal_title=Carcinogenesis; citation_title=Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: Elevated basal activity and sustained response to EGF; citation_author=C. Xing, W. Imagawa; citation_volume=20; citation_publication_date=1999; citation_pages=1201-1208; citation_id=CR320

citation_journal_title=EMBO J.; citation_title=Molecular determinants that mediate selective activation of p38 MAP kinase isoforms; citation_author=H. Enslen, D. M. Brancho, R. J. Davis; citation_volume=19; citation_publication_date=2000; citation_pages=1301-1311; citation_id=CR321

citation_journal_title=J. Biol. Chem.; citation_title=Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis; citation_author=C. C. Zhang, D. J. Shapiro; citation_volume=275; citation_publication_date=2000; citation_pages=479-486; citation_id=CR322

citation_journal_title=Pathol. Res. Pract.; citation_title=Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer; citation_author=M. Hori, S. Inagawa, J. Shimazaki, M. Itabashi; citation_volume=196; citation_publication_date=2000; citation_pages=817-826; citation_id=CR323

citation_journal_title=J. Biol. Chem.; citation_title=The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin; citation_author=E. Cocolakis, S. Lemay, S. Ali, J. J. Lebrun; citation_volume=276; citation_publication_date=2001; citation_pages=18430-18436; citation_id=CR324

citation_journal_title=Exp. Cell Res.; citation_title=The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells; citation_author=R. Seidman, I. Gitelman, O. Sagi, S. B. Horwitz, M. Wolfson; citation_volume=268; citation_publication_date=2001; citation_pages=84-92; citation_id=CR325

citation_journal_title=Structure; citation_title=Structural basis of inhibitor selectivity in MAP kinases; citation_author=Z. Wang, B. J. Canagarajah, J. C. Boehm, S. Kassisa, M. H. Cobb, P. R. Young, S. Abdel-Meguid, J. L. Adams, E. J. Goldsmith; citation_volume=6; citation_publication_date=1998; citation_pages=1117-1128; citation_id=CR326

citation_journal_title=Pharmacol. Ther.; citation_title=p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials; citation_author=J. C. Lee, S. Kassis, S. Kumar, A. Badger, J. L. Adams; citation_volume=82; citation_publication_date=1999; citation_pages=389-397; citation_id=CR327

citation_journal_title=Curr. Opin. Investig. Drugs; citation_title=VX-745. Vertex Pharmaceuticals; citation_author=J. J. Haddad; citation_volume=2; citation_publication_date=2001; citation_pages=1070-1076; citation_id=CR328

citation_journal_title=Blood; citation_title=Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu; citation_author=T. Hideshima, M. Akiyama, T. Hayashi, P. Richardson, R. Schlossman, D. Chauhan, K. C. Anderson; citation_volume=101; citation_publication_date=2003; citation_pages=703-705; citation_id=CR329

citation_journal_title=Bioorg. Med. Chem. Lett.; citation_title=Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase; citation_author=J. E. Stelmach, L. Liu, S. B. Patel, J. V. Pivnichny, G. Scapin, S. Singh, C. E. Hop, Z. Wang, J. R. Strauss, P. M. Cameron, E. A. Nichols, S. J. O'Keefe, E. A. O'Neill, D. M. Schmatz, C. D. Schwartz, C. M. Thompson, D. M. Zaller, J. B. Doherty; citation_volume=13; citation_publication_date=2003; citation_pages=277-280; citation_id=CR330

citation_journal_title=Clin. Cancer Res.; citation_title=C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma; citation_author=Y. M. Yang, F. Bost, W. Charbono, N. Dean, R. McKay, J. S. Rhim, C. Depatie, D. Mercola; citation_volume=9; citation_publication_date=2003; citation_pages=391-401; citation_id=CR331

citation_journal_title=Int. J. Cancer; citation_title=Roles of JNK-1 and p38 in selective induction of apoptosis by capsaicin in ras-transformed human breast epithelial cells; citation_author=H. J. Kang, Y. Soh, M. S. Kim, E. J. Lee, Y. J. Surh, H. R. Kim, S. H. Kim, A. Moon; citation_volume=103; citation_publication_date=2003; citation_pages=475-482; citation_id=CR332

citation_journal_title=Cancer Res.; citation_title=Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells; citation_author=W. Yu, Q. Y. Liao, F. M. Hantash, B. G. Sanders, K. Kline; citation_volume=61; citation_publication_date=2001; citation_pages=6569-6576; citation_id=CR333

citation_journal_title=J. Neurosci.; citation_title=Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway; citation_author=A. C. Maroney, M. A. Glicksman, A. N. Basma, K. M. Walton, E. Knight, C. A. Murphy, B. A. Bartlett, J. P. Finn, T. Angeles, Y. Matsuda, N. T. Neff, C. A. Dionne; citation_volume=18; citation_publication_date=1998; citation_pages=104-111; citation_id=CR334

citation_journal_title=J. Neurochem.; citation_title=Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity; citation_author=A. Bodner, A. C. Maroney, J. P. Finn, G. Ghadge, R. Roos, R. J. Miller; citation_volume=82; citation_publication_date=2002; citation_pages=1424-1434; citation_id=CR335

citation_journal_title=J. Neurosci.; citation_title=Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons; citation_author=C. A. Harris, M. Deshmukh, B. Tsui-Pierchala, A. C. Maroney, E. M. Johnson; citation_volume=22; citation_publication_date=2002; citation_pages=103-113; citation_id=CR336

citation_journal_title=Mol. Cell. Biol.; citation_title=The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis; citation_author=Z. Xu, A. C. Maroney, P. Dobrzanski, N. V. Kukekov, L. A. Greene; citation_volume=21; citation_publication_date=2001; citation_pages=4713-4724; citation_id=CR337

Thông tin
Thông tin xuất bản

Journal of Mammary Gland Biology and Neoplasia

Tập 8 Số 1

45-73

Thông tin tác giả